Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
Private Bag X828, PRETORIA, 0001. Civitas Building Cnr Thabo Sehume & Struben Streets, PRETORIA 0001 Directorate: Access to Affordable Medicines Tel: (012) 395 8130 Fax: (012) 395 8823/4
Enquiries: CPA Ref: HP06-2021SVP e-mail: [email protected]
CONTRACT NUMBER HP06-2021SVP: SUPPLY AND DELIVERY OF SMALL VOLUME PARENTERALS AND INSULIN DEVICES TO THE DEPARTMENT OF HEALTH FOR THE
PERIOD OF 01 MAY 2021 TO 30 APRIL 2024
ADDENDUM 1: REPLACEMENT OF VERSION 1 CONTRACT CIRCULAR
Please note that awards for Safeline Pharmaceuticals (Pty) Ltd and Fresenius Kabi South Africa (Pty) Ltd has been processed and included in this contract circular. Kindy replace version 1 of the Contract Circular of HP06-2021SVP with version 2, attached as Annexure A to this addendum.
Yours faithfully
K JAMALOODIEN DIRECTOR: AFFORDABLE MEDICINES DATE:
15 April 2021
NES TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 OCTOBER 2019 TO 30 SEPTEMBER 2021
health
Department: Health REPUBLIC OF SOUTH AFRICA
Private Bag X828, PRETORIA, 0001. Civitas Building Cnr Thabo Sehume & Struben Streets, PRETORIA 0001 Directorate: Affordable Medicines, Tel: (012) 395 8530 Fax: (012) 395 8823/4
Enquiries: [email protected] Ref: HP06-2021SVP
HP06-2021SVP: SUPPLY AND DELIVERY OF SMALL VOLUME PARENTERALS AND
INSULIN DEVICES TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 MAY 2021 TO 30 APRIL 2024
1. The attached contract circular is for your information.
2. This contract will be subject to the General Conditions of Contract issued in accordance with Chapter 16A of the Treasury Regulations published in terms of the Public Finance Management Act, 1999 (Act 1 of 1999). The Special Requirements and Conditions of Contract are supplementary to the General Conditions of Contract. Where, however, the Special Requirements and Conditions of Contract are in conflict with the General Conditions of the Contract, the Special Requirements and Conditions of Contract will prevail.
3. The bid price offered applies to the product specified e.g. price per single unit, as per specification.
4. The following provincial Departments of Health will participate in this contract:
PARTICIPANTS CONTACT PERSON TEL NO E-MAIL
Eastern Cape Mr C Dlova (047) 532-5536 [email protected]
Free State Ms M Smits (051) 411-0525 [email protected]
Gauteng Mr DS Malele (011) 628-9131 [email protected]
Kwazulu-Natal MS SB Nhlapo (035) 901-7004 [email protected]
Limpopo Mr TS Rasekele (015) 223-9065 [email protected]
Mpumalanga Mr T Moralo (013) 283-9001 [email protected]
North West Mr M Gutta (018) 384-4838 [email protected]
Northern Cape Ms E Delport (053) 830-2717 [email protected]
Western Cape Mr N Mia (021) 483-5800 [email protected]
K JAMALOODIEN DIRECTOR: AFFORDABLE MEDICINES For: DIRECTOR-GENERAL: HEALTH DATE: 15 April 2021
NES TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 OCTOBER 2019 TO 30 SEPTEMBER 2021
HP06-2021SVP: SUPPLY AND DELIVERY OF SMALL VOLUME PARENTERALS AND INSULIN DEVICES TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 MAY 2021 TO 30 APRIL 2024 (PAGE 2)
1. IMPORTANT GENERAL INFORMATION
1.1 Please note that two supplier codes are listed for each supplier. This is to provide for the required supplier registration on the
Central Supplier Database (CSD) at National Treasury.
1.2 Please note that the delivered price is for the unit of measure (UOM) offered. Unit of Measure, National Stock Numbers and prices
should be carefully matched when placing or executing orders.
1.3 All prices are inclusive of 15 % VAT.
1.4 All prices are on a delivered basis.
1.5 Contact persons and e-mail addresses indicated hereunder are to be used for contract enquiries and not for orders.
2. NAMES AND ADDRESSES OF CONTRACTORS AND CONTACT DETAIL
Supplier Name Supplier Code CSD Code Postal Address Contact Person
Telephone / Cellphone Number
Abbott Laboratories South Africa (Pty) Ltd
V2150 MAAA0030395 219 Golf Club Terrace CONSTANTIA KLOOF 1709
Maxine Smith (011) 858-2379 (060) 579-7944
AbbVie (Pty) Ltd V3PG3 MAAA0076921 P O Box 4840 WELTEVREDEN PARK 1709
Sarona Radley (011) 831-3200 (060) 348-9941
Accord Healthcare (Pty) Ltd
V2MB8 MAAA0005335 Private Bag X51 RIVONIA 2128
Reslan Nagoor (011) 234-5703 (082) 494-2510
Actor Pharma (Pty) Ltd V2G28 MAAA0183044 P O Box 7408 HALFWAY HOUSE 1685
Malcolm Blane s (011) 312-3812 (082) 551-4010
Adcock Ingram Critical Care (Pty) Ltd
V4222 MAAA0010153 P O Box 6888 JOHANNESBURG 2000
Vusani Matshidza (011) 494-8129 (079) 894-7873
HP06-2021SVP: SUPPLY AND DELIVERY OF SMALL VOLUME PARENTERALS AND INSULIN DEVICES TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 MAY 2021 TO 30 APRIL 2024
(PAGE 3)
Supplier Name Supplier Code CSD Code Postal Address Contact Person
Telephone / Cellphone Number
Adcock Ingram Healthcare (Pty) Ltd
V2272 MAAA0036413 Private Bag X69 BRYANSTON 2021
Nkosinathi.Mthethwa (011) 635-0103 (072) 328-1179
Ascendis Pharma (Pty) Ltd V0DM6 MAAA0043637 Postnet Suite #252 Private Bag X21 BRYANSTON 2021
Marnus Sonnekus (011) 036-9600 (082) 329-8225
B Braun Medical (Pty) Ltd VYL89 MAAA0040832 P O Box 1787 RANDBURG 2125
Walda Van Zyl (010) 222-3000 (073) 494-8695
Biotech Laboratories (Pty) Ltd
VUV35 MAAA0029826 Private Bag X65 HALFWAY HOUSE 1685
Faried Dean (011) 848-3050 (082) 455-1149
Equity Pharmaceuticals (Pty) Ltd
V1QZ3 MAAA0007480 100 Sovereign Drive Route 21, Corporate Park Nelmapius Drive IRENE 0157
Carel Bouwer (012) 345-1747 (082) 879-8866
Ferring (Pty) Ltd VXY92 MAAA0005879 Route 21, Corporate Park 6 Regency Drive IRENE 0157
Martha van Zyl (012) 443-4307 (082) 565-2656
[email protected] [email protected]
Fresenius Kabi SA (Pty) Ltd
VAJL3 MAAA0007374 P O Box 4156 HALFWAY HOUSE 1685
Jeannine Terblanche (011) 545 0000 [email protected]
Lundbeck SA (Pty) Ltd VVS90 MAAA0031052 P O Box 2171 NORTHRIDING 2162
Julianne Howarth (011) 699-1600 (078) 800-3843
Litha Pharma (Pty) Ltd (Acino Pharma)
VGS73 MAAA0009244 P O Box 8356 MIDRAND 1685
Anand Reddy (011) 516-1700 (066) 304-6900
HP06-2021SVP: SUPPLY AND DELIVERY OF SMALL VOLUME PARENTERALS AND INSULIN DEVICES TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 MAY 2021 TO 30 APRIL 2024
(PAGE 4)
Supplier Name Supplier Code CSD Code Postal Address Contact Person
Telephone / Cellphone Number
Macleods Pharmaceuticals SA (Pty) Ltd
V3PJ1 MAAA0007167 Office Block 1, Bassonia Estate Office Park (East) 1 Cussonia Drive Bassonia Rock Ext 12 ALBERTON 2061
Vanita Rajool (011) 628-1169 (083) 266-9223
Mylan (Pty) Ltd V3PS6 MAAA0081441 Postnet Suite X23 Private Bag X10010 EDENVALE 1610
Kumaraswamy Ekhambaram
(011) 451-1300 (071) 473-3900
Novartis SA (Pty) Ltd VBVW2 MAAA0006317 Magula Cresent West, Waterfall City Lukskei Vlei MIDRAND 2090
Masego Masipa (011) 347-6600 (082) 805-1262
Novo Nordisk (Pty) Ltd V2743 MAAA0013414 P O Box 783155 SANDTON 2146
Venkata Kalyan Papa Konduri
(011) 202-0500 (079) 694-1953
P & G South African Trading (Pty) Ltd
VJDY7 MAAA0913191 Private Bag X10062 SANDTON 2196
Deon Labuschagne (010) 001-9650 (082) 897-3611
Pfizer Laboratories (Pty) Ltd
V2189 MAAA0019202 85 Bute Lane SANDTON 2146
Themba Mnguni (011) 320-6091 (082) 307-9658
Pharmacare Limited V2205 MAAA0008452 P O Box 1587 GALLO MANOR 2052
Itumeleng Mathe (011) 239-6243 (083) 298-4366
HP06-2021SVP: SUPPLY AND DELIVERY OF SMALL VOLUME PARENTERALS AND INSULIN DEVICES TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 MAY 2021 TO 30 APRIL 2024
(PAGE 5)
Supplier Name Supplier Code CSD Code Postal Address Contact Person
Telephone / Cellphone Number
Pharmaco Distribution (Pty) Ltd
VBVW1 MAAA0044115 P O Box 786522 SANDTON 2146
Jan van den Berg (011) 784-0077 (082) 572-7832
Pharma-Q (Pty) Ltd V1NK1 MAAA0016762 Private Bag X09 FLORIDA 1710
Anand Mehta (011) 247-1600 (083) 636-4444
Piramal Critical Care SA (Pty) Ltd
VFPD3 MAAA0655823 P O Box 1088 CRESTA 2188
Divya Ranchod (011) 678-1948 (082) 454-1781
Ranbaxy Pharmaceuticals (Pty) Ltd
V4728 MAAA0000384 P O Box 43486 INDUSTRIA 2042
Deepakh Sewnarain (012) 643-2000 (082) 893-8649
Safeline Pharmaceuticals (Pty) Ltd
VZL63 MAAA0002530 P O Box 7900 PALMCOURT 1709
Kay Naidu (011) 288-5360 (082) 459-2709
Sandoz SA (Pty) Ltd VVZ69 MAAA0011663 P O Box 12257 VORNA VALLEY 1686
Renee Moodley (011) 545-0424 (083) 704-1806
Sanofi-Aventis SA (Pty) Ltd
V2160 MAAA0009069 Private Bag X207 MIDRAND 1685
Jaidev Maharaj (011) 847-5264 (082) 943-3952
Specpharm (Pty) Ltd V3EQ1 MAAA0009737 P O Box 651 HALFWAY HOUSE 1685
Gregory Hill (011) 652-0465 (073) 676-0775
Unimed Healthcare (Pty) Ltd
V92D6 MAAA0444639 Private Bag X12 PRETORIA WEST 0117
Arshad Bera (011) 056- 6999 (083) 647-7860
HP06-2021SVP: SUPPLY AND DELIVERY OF SMALL VOLUME PARENTERALS AND INSULIN DEVICES TO THE DEPARTMENT OF HEALTH
CONTRACT CIRCULARVERSION 2
FOR THE PERIOD 01 MAY 2021 TO 30 APRIL 2024
Item No Item Specification *ADD Estimate Quantity Awarded
Split Supplier Name Central Supplier Database Number
Supplier CodeV-Number
Registered Product Name Delivered Price
Pack Size Offered: Unit Pack
Lead-Time (≤ 14 calendar
days)
MOQ Total Score
National Stock Number
UOM
1 Acetylcysteine 200mg/ml, injection, 10ml 213 295 213 295 100% Equity Pharmaceuticals (Pty) Ltd MAAA0007480 V1QZ3 Paradote R196.00 1 x 10 vials 14 1 x 10 vials 91.00 181915188 VI
2 Adenosine 3mg/ml, injection, 2ml 74 740 74 740 100% Sanofi-Aventis SA (Pty) Ltd MAAA0009069 V2160 ADENOCOR VIALS 6MG / 2ML 6 R156.21 1 x 1 14 6 91.00 180373081 VI
3 Adrenaline (Epinephrine) 0.15mg/0.3ml, auto-injection, 0.3ml
5 570 5 570 100% Mylan (Pty) Ltd MAAA0081441 V3PS6 EPIPEN JUNOR AUTO-INJECTOR R760.00 1 x 1 14 10 93.00 222000173 EA
4 Adrenaline (Epinephrine) 0.3mg/0.3ml, auto-injection, 0.3ml
2 336 2 336 100% Mylan (Pty) Ltd MAAA0081441 V3PS6 EPIPEN R749.00 1 x 1 14 10 93.00 222000174 EA
5 Adrenaline (Epinephrine) 1mg/ml, injection, 1ml
7 520 710 6 768 639 90% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Adrenaline Inj 1mg/1ml R4.00 1 x 10 14 500 96.00 180075485 AM
5 Adrenaline (Epinephrine) 1mg/ml, injection, 1ml
Product awarded:Adrenaline (Epinephrine) 1mg/ml, injection, 1mlRemaining shelf life: 4 - 10 months
1
752 071 10% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 ADRENALINE FRESENIUS 1 mg/1 ml (1:1000) R4.84 1 x 1 14 10 Amps 72.10 180075485 AM
6 Alfentanil 0.5mg/ml, injection, 2ml 119 310 119 310 100% Piramal Critical Care SA (Pty) Ltd MAAA0655823 VFPD3 Rapifen 2ml R49.83 5 x 2ml amps 14 5 x 2ml amps 90.00 180075489 AM
7 Alprostadil 0.5mg/ml, injection, 1ml
Product awarded:Alprostadil 0.5mg/ml, injection, 1ml1 pack of 5 injections
Price vs Pack size:1 x 1 injection = R2,744.601 x 5 injections = R13,723.09
6 250 6 250 100% Pfizer Laboratories (Pty) Ltd MAAA0019202 V2189 PROSTIN VR R2 744.60 1 x 5 14 5 91.00 180075498 AM
9 Aminophylline 25mg/ml, injection, 10ml 354 560 354 560 100% Adcock Ingram Critical Care (Pty) Ltd MAAA0010153 V4222 Sabax Aminophylline IV R3.57 1 x 10 vials 14 10 99.87 189700102 AM
10 Amiodarone 50mg/ml, injection, 3ml 223 660 223 660 100% Sanofi-Aventis SA (Pty) Ltd MAAA0009069 V2160 CORDARONE X IV 150MG/3ML 6 R61.09 1 x 1 14 6 91.00 180075509 AM
11 Atracurium 10mg/ml, injection, 2.5ml 81 270 81 270 100% Pharmacare Limited MAAA0008452 V2205 Tracrium Inj 5x2.5ml R78.66 5 x 2.5ml 14 5 95.00 180075518 AM
12 Atracurium 10mg/ml, injection, 5ml 58 400 58 400 100% Pharmacare Limited MAAA0008452 V2205 Tracrium Inj 5x5ml R158.41 5 x 5ml 14 5 95.00 180075520 AM
13 Atropine 0.5mg/ml, injection, 1ml 1 278 840 1 023 072 80% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Atropine Inj. 0,5mg/1ml R4.00 1 x 10 14 500 96.00 189707023 AM
13 Atropine 0.5mg/ml, injection, 1ml1
1 278 840 255 768 20% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 ATROPINE SULPHATE FRESENIUS 0.5 mg/1 ml R4.43 1 x 1 14 10 Amps 81.33 189707023 AM
14 Atropine 1mg injection, 1ml 2 353 110 1 882 488 80% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Atropine Inj. 1mg/1ml R4.20 1 x 10 14 400 96.00 189707024 AM
14 Atropine 1mg injection, 1ml 1 2 353 110 470 622 20% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 ATROPINE SULPHATE FRESENIUS 1.0 mg/1 ml R4.78 1 x 1 14 10 Amps 78.57 189707024 AM
15 Betamethasone 4mg/ml, injection, 1ml 1 199 860 1 199 860 100% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Betamethasone 4mg/1ml R4.75 1 x 10 14 400 96.00 180075545 AM
16 Biperiden 5mg, injection, 1ml 63 180 63 180 100% Pharmaco Distribution (Pty) Ltd MAAA0044115 VBVW1 AKINETON R45.17 1 x 5 14 5 90.00 180075548 AM
17 Bupivacaine 5mg, Adrenaline 5mcg/ml, injection, 20ml
292 780 292 780 100% Adcock Ingram Critical Care (Pty) Ltd MAAA0010153 V4222 MACAINE HCL 0,5% INJECTION WITH ADRENALINE
R31.05 1 x 10 vials 14 10 100.00 180075555 AM
18 Bupivacaine 5mg, Dextrose Anhydrous 72.7mg/ml, injection, 4ml
974 370 974 370 100% Adcock Ingram Critical Care (Pty) Ltd MAAA0010153 V4222 MACAINE HCL 0.5% SPINAL INJECTION WITH DEXTROSE
R4.60 1 x 10 14 10 100.00 180075556 AM
19 Bupivacaine 5mg/ml injection, spinal, 4ml 206 140 206 140 100% Adcock Ingram Critical Care (Pty) Ltd MAAA0010153 V4222 MACAINE HCL 0.5% SPINAL INJECTION R16.68 1 x 10 14 10 100.00 180075553 AM
Page 1 of 8
HP06-2021SVP: SUPPLY AND DELIVERY OF SMALL VOLUME PARENTERALS AND INSULIN DEVICES TO THE DEPARTMENT OF HEALTH
CONTRACT CIRCULARVERSION 2
FOR THE PERIOD 01 MAY 2021 TO 30 APRIL 2024
Item No Item Specification *ADD Estimate Quantity Awarded
Split Supplier Name Central Supplier Database Number
Supplier CodeV-Number
Registered Product Name Delivered Price
Pack Size Offered: Unit Pack
Lead-Time (≤ 14 calendar
days)
MOQ Total Score
National Stock Number
UOM
20 Bupivacaine 5mg/ml, injection, 10ml 971 660 971 660 100% Adcock Ingram Critical Care (Pty) Ltd MAAA0010153 V4222 MACAINE HCL 0.5% INJECTION R6.90 1 x 10 14 10 100.00 180075551 AM
21 Caffeine 20mg/ml, injection, 1ml 1 185 250 185 250 100% Safeline Pharmaceuticals (Pty) Ltd MAAA0002530 VZL63 CAYONA 20mg/ml R380.73 1 x 1 14 100 92.00 222001198 EA
22 Calcium gluconate 10% m/v, injection, 10ml 1 754 340 754 340 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 CALCIUM GLUGONATE FRESENIUS R12.65 1 x 1 14 10 Amps 91.00 180075565 AM
23 Cisatracurium 2mg/ml, injection, 2.5 ml 266 650 239 985 90% Accord Healthcare (Pty) Ltd MAAA0005335 V2MB8 Cistrax 5mg/2.5ml R25.30 1 x 5 14 20 91.00 181767288 AM
23 Cisatracurium 2mg/ml, injection, 2.5 ml 266 650 26 665 10% 181767288 AM
24 Cisatracurium 2mg/ml, injection, 5ml 237 390 166 173 70% Accord Healthcare (Pty) Ltd MAAA0005335 V2MB8 Cistrax 10mg/5ml R37.95 1 x 5 14 20 91.00 180308024 AM
24 Cisatracurium 2mg/ml, injection, 5ml 237 390 71 217 30% 180308024 AM
26 Clotiapine 10mg/ml, injection, 4ml 78 395 78 395 100% Pharmaco Distribution (Pty) Ltd MAAA0044115 VBVW1 ETOMINE R28.72 1 x 10 14 10 90.00 180075729 AM
29 Desmopressin 4mcg, injection, 1ml 9 660 9 660 100% Ferring (Pty) Ltd MAAA0005879 VXY92 DDAVP INJECTION 4MCG/ML 1ML R97.95 1 x 10 ampoules per
pack
14 5 x 10 ampoules pack (50
ampoules)
90.00 180075757 AM
30 Dexamethasone 4mg, injection, 1ml 5 270 300 4 743 270 90% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Dexamethasone Phosphate Inj. 4mg/1ml R5.40 1 x 10 14 400 96.00 180075759 AM
30 Dexamethasone 4mg, injection, 1ml 1 5 270 300 527 030 10% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 FRESENIUS DEXAMETHASONE 4 mg/1 ml R8.70 1 x 1 14 10 Amps 36.00 180075759 AM
31 Dexmedetomidine, 100 mcg/ml, Injection for infusion, 2ml
Product awarded:Dexmedetomidine, 100 mcg/ml, Injection for infusion, 2ml1 pack of 5 injections
Price vs Pack size:1 x 1 injection = R510.821 x 5 injections = R2,554.10
58 320 58 320 100% Pfizer Laboratories (Pty) Ltd MAAA0019202 V2189 PreceDEX R510.82 1 x 5 14 5 91.00 181937349 AM
32 Dextrose 50% m/v, injection, 20ml 1 1 293 980 1 293 980 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 DEXTROSE FRESENIUS 50 % (20 ml) INJECTION R19.81 1 x 1 14 10 Amps 91.00 180075794 AM
33 Dextrose 50% m/v, injection, 50ml 1 1 140 740 1 140 740 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 DEXTROSE-FRESENIUS 50% (50ml) R28.55 1 x 1 14 60 Bags 91.00 180352804 BG
34 Diazepam 5mg/ml, injection, 2ml 771 330 771 330 100% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Diazepam Inj. 10mg/2ml R4.00 1 x 10 14 400 96.00 180075798 AM
35 Diclofenac 25mg/ml, injection, 3ml 8 327 390 6 661 912 80% Unimed Healthcare (Pty) Ltd MAAA0444639 V92D6 Diclofenac Injection Unimed R1.52 1 x 50 14 750 100.00 180075799 AM
35 Diclofenac 25mg/ml, injection, 3ml 8 327 390 1 665 478 20% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Dicon 75 inj R1.65 1 x 50 14 500 88.30 180075799 AM
36 Digoxin 0,25mg/ml, injection, 2ml 39 280 39 280 100% Pharmacare Limited MAAA0008452 V2205 Lanoxin 0.5mg Inj 5 x 2ml R21.39 5 x 2ml 14 5 95.00 180075803 AM
38 Dobutamine 12.5mg/ml, injection, 20ml 1 206 440 206 440 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 DOBUTAMINE FRESENIUS 250 mg/20 ml R75.44 1 x 1 14 5 Amps 91.00 189715235 VI
39 Dopamine 40mg/ml, injection, 5ml 106 755 106 755 100% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Dopamine Concentrate Inj. 200mg/5ml R7.80 1 x 10 14 250 96.00 180075879 AM
40 Enoxaparin 40mg, injection, 0.4ml 8 663 680 8 663 680 100% Sanofi-Aventis SA (Pty) Ltd MAAA0009069 V2160 CLEXANE PF SYRINGE 40mg 10 X 0.4ML R53.61 1 x 1 14 10 91.00 180077964 SG
41 Enoxaparin 60mg, injection, 0.6ml 901 800 901 800 100% Sanofi-Aventis SA (Pty) Ltd MAAA0009069 V2160 CLEXANE PF SYRINGE 60mg 10 X 0.6ML R67.49 1 x 1 14 10 91.00 222000901 SG
TO FOLLOW
TO FOLLOW
Page 2 of 8
HP06-2021SVP: SUPPLY AND DELIVERY OF SMALL VOLUME PARENTERALS AND INSULIN DEVICES TO THE DEPARTMENT OF HEALTH
CONTRACT CIRCULARVERSION 2
FOR THE PERIOD 01 MAY 2021 TO 30 APRIL 2024
Item No Item Specification *ADD Estimate Quantity Awarded
Split Supplier Name Central Supplier Database Number
Supplier CodeV-Number
Registered Product Name Delivered Price
Pack Size Offered: Unit Pack
Lead-Time (≤ 14 calendar
days)
MOQ Total Score
National Stock Number
UOM
42 Enoxaparin 80mg, injection, 0.8ml 2 019 230 2 019 230 100% Sanofi-Aventis SA (Pty) Ltd MAAA0009069 V2160 CLEXANE PF SYRINGE 80mg 10 X 0.8ML R81.50 1 x 1 14 10 91.00 180970533 EA
50 Etomidate 2mg/ml, injection, 10ml 145 080 145 080 100% Piramal Critical Care SA (Pty) Ltd MAAA0655823 VFPD3 Hypnomidate R36.74 5 x 10ml amps 14 5 x 10ml amps 90.00 180075956 AM
51 Fentanyl 0.05mg/ml, injection, 2ml 1 581 570 1 423 413 90% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Fentanyl Inj. 100ug/2ml R4.70 1 x 10 14 400 96.00 180075959 AM
51 Fentanyl 0.05mg/ml, injection, 2ml
Product awarded:Fentanyl 0.05mg/ml, injection, 2ml1 pack of 10 injections
Price vs Pack size:1 x 1 injection = R7.221 x 10 injections = R72.20
1 1 581 570 158 157 10% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 FENTANYL FRESENIUS 100 mcg/2 ml R7.22 1 x 10 14 10 Amps 42.74 180075959 AM
52 Fentanyl 0.05mg/ml, injection, 10ml 370 850 370 850 100% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Fentanyl Inj. 500ug/10ml R10.20 1 x 10 14 200 96.00 180075960 AM
54 Flupenthixol decanoate 20mg/ml, injection, 1ml
1 507 530 1 507 530 100% Lundbeck SA (Pty) Ltd MAAA0031052 VVS90 Fluanxol Depot 20 mg/ml R36.06 1 x 1 14 5 90.00 180017761 AM
55 Furosemide 10mg/ml, injection, 25ml 1 245 280 245 280 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 FRUSEMIDE FRESENIUS 250 mg/25 ml R23.92 1 x 1 14 10 Amps 91.00 180075988 AM
56 Furosemide 10mg/ml, injection, 2ml 7 085 900 7 085 900 100% Adcock Ingram Critical Care (Pty) Ltd MAAA0010153 V4222 ADCO FUROSEMIDE 20MG/2ML R2.97 1 x 10 vials 14 10 100.00 180075982 AM
57 Furosemide 10mg/ml, injection, 5ml 342 230 342 230 100% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Furosemide Inj. 50mg/5ml R5.55 1 x 10 14 300 96.00 180075985 AM
58 Glucagon 1mg, injection, 1ml 30 050 30 050 100% Novo Nordisk (Pty) Ltd MAAA0013414 V2743 GLUCAGEN HYPOKIT R394.98 1 x 1 14 1 92.00 180309135 VI
60 Glycopyrronium bromide 0.2mg/ml, injection, 2ml
622 200 622 200 100% Pharmacare Limited MAAA0008452 V2205 Robinul Inj 2ml R12.84 10 x 2ml 14 10 95.00 180075998 AM
65 Hydrocortisone 100mg/2ml, injection, 2ml 4 166 740 3 750 066 90% Macleods Pharmaceuticals SA (Pty) Ltd MAAA0007167 V3PJ1 Macleods Hydrocortisone Injection R17.37 1 x 2ml 14 100 95.00 180018040 VI
65 Hydrocortisone 100mg/2ml, injection, 2ml
Product awarded:Hydrocortisone 100mg/2ml, injection, 2ml1 pack of 5 injections
Price vs Pack size:1 x 1 injection = R39.341 x 5 injections = R196.70
4 166 740 416 674 10% Pfizer Laboratories (Pty) Ltd MAAA0019202 V2189 SOLU-CORTEF 100mg R39.34 1 x 5 14 5 -22.83 180018040 VI
66 Hyoscine Butylbromide 20mg, injection, 1ml 2 338 110 2 338 110 100% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Hyoscine Butylbromide Inj. 20mg/1ml R5.30 1 x 10 14 300 96.00 180076081 AM
67 Insulin analogue, Human, Long-acting, 100 u/ml, disposable pen, 3ml
33 860 33 860 100% Sanofi-Aventis SA (Pty) Ltd MAAA0009069 V2160 OPTISULIN SOLOSTAR 3ML 5 R51.06 1 x 1 14 5 91.00 222000179 EA
68 Insulin analogue, Human, Ultrafast-acting 100 u/ml, disposable pen, 3ml
229 559 229 559 100% Sanofi-Aventis SA (Pty) Ltd MAAA0009069 V2160 APIDRA SOLOSTAR 100IU/ML 3 ML 5 R72.68 1 x 1 14 5 91.00 222000181 EA
69 Insulin analogue, Human, Ultrafast-acting 100 u/ml, vial, 10ml
1 540 1 540 100% Sanofi-Aventis SA (Pty) Ltd MAAA0009069 V2160 APIDRA VIALS 10ML 1 R244.95 1 x 1 14 10 91.00 222000182 VI
70 Insulin, Biosynthetic, Human, Isophane, 100 u/ml, disposable pen, 3ml
2 832 200 2 832 200 100% Novo Nordisk (Pty) Ltd MAAA0013414 V2743 PROTAPHANE HM R32.06 1 x 5 14 10 92.00 180309126 SG
71 Insulin, Biosynthetic, Human, Isophane, 100 u/ml, vial, 10ml
903 640 903 640 100% Novo Nordisk (Pty) Ltd MAAA0013414 V2743 PROTAPHANE HM R34.14 1 x 1 14 10 92.00 189710587 VI
Page 3 of 8
HP06-2021SVP: SUPPLY AND DELIVERY OF SMALL VOLUME PARENTERALS AND INSULIN DEVICES TO THE DEPARTMENT OF HEALTH
CONTRACT CIRCULARVERSION 2
FOR THE PERIOD 01 MAY 2021 TO 30 APRIL 2024
Item No Item Specification *ADD Estimate Quantity Awarded
Split Supplier Name Central Supplier Database Number
Supplier CodeV-Number
Registered Product Name Delivered Price
Pack Size Offered: Unit Pack
Lead-Time (≤ 14 calendar
days)
MOQ Total Score
National Stock Number
UOM
72 Insulin, Biosynthetic, Human, Biphasic, 100 u/ml, soluble 30% and Isophane 70%, disposable pen, 3ml
13 676 740 13 676 740 100% Novo Nordisk (Pty) Ltd MAAA0013414 V2743 ACTRAPHANE HM R30.37 1 x 5 14 10 92.00 180309129 SG
74 Insulin, Biosynthetic, Human, Biphasic, 100 u/ml, soluble 30% and Isophane 70%, vial, 10ml
4 520 360 4 520 360 100% Novo Nordisk (Pty) Ltd MAAA0013414 V2743 ACTRAPHANE HM R34.14 1 x 1 14 10 92.00 189711634 VI
75 Insulin, Biosynthetic, Human, Soluble, 100 u/ml, disposable pen, 3ml
1 886 440 1 886 440 100% Novo Nordisk (Pty) Ltd MAAA0013414 V2743 ACTRAPID HM R32.06 1 x 5 14 10 92.00 180309128 SG
76 Insulin, Biosynthetic, Human, Soluble, 100 u/ml, vial, 10ml
387 840 387 840 100% Novo Nordisk (Pty) Ltd MAAA0013414 V2743 ACTRAPID HM R34.14 1 x 1 14 10 92.00 189710585 VI
77 Iron dextran containing elemental iron 50mg/ml, injection, 10ml
16 500 16 500 100% Litha Pharma (Pty) Ltd (Acino Pharma) MAAA0009244 VGS73 COSMOFER R310.13 1 x 2 14 1 x 2 100.00 181871852 AM
78 Iron dextran containing elemental iron 50mg/ml, injection, 2ml
211 350 211 350 100% Litha Pharma (Pty) Ltd (Acino Pharma) MAAA0009244 VGS73 COSMOFER R62.03 1 x 5 14 1 x 5 100.00 181891028 AM
79 Iron sucrose containing elemental iron 20mg/ml, injection, 5ml
271 550 271 550 100% Actor Pharma (Pty) Ltd MAAA0183044 V2G28 Rautevene R48.53 5 x 5ml ampules
14 50 90.00 180185678 AM
80 Isulin analogue, Human, Ultrafast-acting 100 u/ml, penfill cartridge for use in pens, 3ml(PENS TO BE PROVIDED FREE OF CHARGE TO PATIENTS)
7 725 7 725 100% Sanofi-Aventis SA (Pty) Ltd MAAA0009069 V2160 APIDRA 300IU CART 5 R69.46 1 x 1 14 5 91.00 222000180 EA
81 Ketamine 10mg/ml, injection, 20ml 1 96 930 96 930 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 KETAMINE FRESENIUS 10 mg/1 ml R37.03 1 x 1 14 10 Vials 91.00 189710933 VI
82 Ketamine 100mg/ml, injection, 10ml 1 61 060 61 060 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 KETAMINE FRESENIUS 100 mg/1 ml R98.39 1 x 1 14 10 Vials 91.00 189706747 VI
83 Ketamine 50mg/ml, injection, 10ml 1 87 050 87 050 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 KETAMINE FRESENIUS 50 mg/1 ml R49.20 1 x 1 14 10 Vials 91.00 189710574 VI
85 Lidocaine 1% m/v, injection, not for iv use, 20ml
1 821 100 1 821 100 100% B Braun Medical (Pty) Ltd MAAA0040832 VYL89 Lignocaine-HCL B.Braun 1% 20ml (Product Code: 3659091)
R8.38 1 x 1 14 20 96.00 180076306 VI
86 Lidocaine 10% m/v, iv injection, 5ml 1 39 220 39 220 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 LIGNOCAINE HCI FRESENIUS 10% (AMPOULES) R12.07 1 x 1 14 10 Amps 91.00 180076360 AM
87 Lidocaine 2% m/v injection, not for iv use, 20ml
1 191 930 1 191 930 100% B Braun Medical (Pty) Ltd MAAA0040832 VYL89 Lignocaine-HCL B.Braun 2% 20ml (Product Code: 3659089)
R8.67 1 x 1 14 20 96.00 189703157 VI
88 Lidocaine 2% m/v, Adrenaline 12.5mcg (1:80 000), dental cartridge, 1.8ml
18 119 370 18 119 370 100% Adcock Ingram Healthcare (Pty) Ltd MAAA0036413 V2272 Xylotox E80-A 6.79 100 x 1.8ml box 14 1 x 100 x 1.8ml 100.00 180076312 CA
89 Lidocaine 2% m/v, dental cartridge, 1.8ml 2 814 860 2 814 860 100% Adcock Ingram Healthcare (Pty) Ltd MAAA0036413 V2272 Xylotox S.E. Plain 6.79 100 x 1.8ml box 14 1 x 100 x 1.8ml 99.93 180076343 CA
90 Lidocaine 2% m/v, iv injection, 5ml 1 964 420 1 964 420 100% B Braun Medical (Pty) Ltd MAAA0040832 VYL89 Lignocaine-HCL B. Braun 2% 5ml (Product Code: 3659970)
R2.89 1 x 1 14 20 96.00 180076308 AM
92 Magnesium sulfate 50%, injection, 2ml 5 111 040 5 111 040 100% Adcock Ingram Critical Care (Pty) Ltd MAAA0010153 V4222 SABAX MAGNESIUM SULPHATE 50% R3.45 1 x 10 vials 14 10 100.00 189710942 AM
93 Mannitol 25% m/v, injection, 50ml
Product awarded:Mannitol 25% m/v, injection, 50ml1 pack of 60 bagsRemaining shelf life: 4 - 10 months
Price vs Pack size:1 x 1 bag = R49.511 x 60 bags = R2,970.60
1 19 320 19 320 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 MANNITOL FRESENIUS 25 % INJECTION R49.51 1 x 1 14 60 Bags 91.00 189704505 AM
96 Methylprednisolone 500mg, (as sodium succinate) injection, 8ml
100 830 100 830 100% Pfizer Laboratories (Pty) Ltd MAAA0019202 V2189 SOLU-MEDROL 500mg R159.91 1 x 1 14 1 91.00 189710955 VI
97 Methylprednisolone acetate 40mg/ml, injection, 2ml
257 150 257 150 100% Pfizer Laboratories (Pty) Ltd MAAA0019202 V2189 DEPO-MEDROL 40 mg R34.88 1 x 1 14 1 91.00 189710776 VI
Page 4 of 8
HP06-2021SVP: SUPPLY AND DELIVERY OF SMALL VOLUME PARENTERALS AND INSULIN DEVICES TO THE DEPARTMENT OF HEALTH
CONTRACT CIRCULARVERSION 2
FOR THE PERIOD 01 MAY 2021 TO 30 APRIL 2024
Item No Item Specification *ADD Estimate Quantity Awarded
Split Supplier Name Central Supplier Database Number
Supplier CodeV-Number
Registered Product Name Delivered Price
Pack Size Offered: Unit Pack
Lead-Time (≤ 14 calendar
days)
MOQ Total Score
National Stock Number
UOM
98 Methylprednisolone acetate 40mg/ml, injection, 5ml
18 412 18 412 100% Pfizer Laboratories (Pty) Ltd MAAA0019202 V2189 DEPO-MEDROL 40 mg R97.18 1 x 1 14 1 91.00 189710775 VI
99 Metoclopramide 5mg/ml, injection, 2ml 7 601 990 760 199 10% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Metoclopramide Inj 10mg/2ml R3.45 1 x 10 14 400 44.86 180076396 AM
99 Metoclopramide 5mg/ml, injection, 2ml 7 601 990 6 841 791 90% 180076396 AM
100 Midazolam 1mg/ml, injection, 5ml 595 200 357 120 60% Adcock Ingram Critical Care (Pty) Ltd MAAA0010153 V4222 ADCO MIDAZOLAM INJECTION 5MG/5ML R6.21 1 x 10 14 10 92.80 180076401 AM
100 Midazolam 1mg/ml, injection, 5ml 595 200 238 080 40% Accord Healthcare (Pty) Ltd MAAA0005335 V2MB8 Accord Midazolam 5 mg/5 ml R5.75 1 x 10 14 20 91.00 180076401 AM
101 Midazolam 5mg/ml, injection, 10ml 127 300 127 300 100% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Midazolam Inj. 50mg/10ml R19.25 1 x 10 14 100 96.00 180018352 AM
102 Midazolam 5mg/ml, injection, 3ml 948 930 569 358 60% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Midazolam Inj. 15mg/3ml R7.50 1 x 5 14 300 96.00 180076404 AM
102 Midazolam 5mg/ml, injection, 3ml
Product awarded:Midazolam 5mg/ml, injection, 3ml1 pack of 10 injections
Price vs Pack size:1 x 1 injection = R8.171 x 10 injections = R81.70
948 930 379 572 40% Adcock Ingram Critical Care (Pty) Ltd MAAA0010153 V4222 ADCO MIDAZOLAM INJECTION 15MG/3ML R8.17 1 x 10 14 10 91.96 180076404 AM
103 Morphine 10mg/ml, injection, 1ml 3 307 110 2 976 399 90% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Morphine Inj. 10mg/1ml R3.90 1 x 10 14 300 96.00 189703413 AM
103 Morphine 10mg/ml, injection, 1ml 1 3 307 110 330 711 10% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 MORPHINE SULPHATE FRESENIUS PF 10 mg/1 ml
R5.24 1 x 1 14 10 Amps 60.08 189703413 AM
104 Morphine 15mg/ml, injection, 1ml 1 772 750 1 595 475 90% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Morphine Inj. 15mg/1ml R4.10 1 x 10 14 300 96.00 189700425 AM
104 Morphine 15mg/ml, injection, 1ml 1 1 772 750 177 275 10% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 MORPHINE SULPHATE FRESENIUS PF 15 mg/1 ml
R5.35 1 x 1 14 10 Amps 63.56 189700425 AM
105 Naloxone 0.02mg/ml, injection, 2ml 1 96 540 96 540 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 NALOXONE HCI NEONATAL FRESENIUS 0.02 mg/1 ml
R9.05 1 x 1 14 10 Amps 91.00 189708068 AM
106 Naloxone 0.4mg/ml, injection, 1ml 1 504 980 504 980 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 NALOXONE HCI FRESENIUS 0.4 mg/1 ml R7.61 1 x 1 14 10 Amps 91.00 189705061 AM
109 Needle, Insulin, 31G x 5mm, sterile, suitable for use with all prefilled insulin injection devices, 100
82 770 82 770 100% Unimed Healthcare (Pty) Ltd MAAA0444639 V92D6 INSUPEN 31g X 5mm R60.02 1 x 100 14 36 95.61 181915212 BX
110 Needle, Insulin, 31G x 8mm, sterile, suitable for use with all prefilled insulin injection devices, 100
377 460 377 460 100% Unimed Healthcare (Pty) Ltd MAAA0444639 V92D6 INSUPEN 31g X 8mm R56.48 1 x 100 14 36 99.10 181915214 BX
112 Neostigmine 2.5mg, injection, 1ml 481 450 481 450 100% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Neostigmine Methyl Sulphate Inj. 2.5mg/1ml
R6.16 1 x 10 14 200 96.00 180089506 AM
113 Octreotide 0.05mg, injection, 1ml 14 020 14 020 100% Novartis SA (Pty) Ltd MAAA0006317 VBVW2 Sandostatin 0.05mg R 104.36 1 x 5 14 1 91.00 180076442 AM
114 Octreotide 0.1mg, injection, 1ml 119 395 119 395 100% Novartis SA (Pty) Ltd MAAA0006317 VBVW2 Sandostatin 0.1mg R 199.10 1 x 5 14 1 91.00 180076445 AM
116 Oxytocin 10 iu, injection, 1ml 6 406 260 3 203 130 50% Specpharm (Pty) Ltd MAAA0009737 V3EQ1 Spec Oxytocin 10iu R15.25 1 x 10 14 1 pack of 10's 99.00 180076472 AM
117 Oxytocin 5 iu, injection, 1ml 2 063 960 1 031 980 50% Specpharm (Pty) Ltd MAAA0009737 V3EQ1 Spec Oxytocin 5iu R14.77 1 x 10 14 1 pack of 10's 99.00 180076470 AM
118 Oxytocin 5iu, Ergometrine 0.5mg, injection, 1ml
538 290 538 290 100% Adcock Ingram Critical Care (Pty) Ltd MAAA0010153 V4222 SYNTOMETRINE R27.85 1 x 5 14 5 100.00 180076474 AM
TO FOLLOW
Page 5 of 8
HP06-2021SVP: SUPPLY AND DELIVERY OF SMALL VOLUME PARENTERALS AND INSULIN DEVICES TO THE DEPARTMENT OF HEALTH
CONTRACT CIRCULARVERSION 2
FOR THE PERIOD 01 MAY 2021 TO 30 APRIL 2024
Item No Item Specification *ADD Estimate Quantity Awarded
Split Supplier Name Central Supplier Database Number
Supplier CodeV-Number
Registered Product Name Delivered Price
Pack Size Offered: Unit Pack
Lead-Time (≤ 14 calendar
days)
MOQ Total Score
National Stock Number
UOM
119 Pantoprazole 40mg, injection, 10ml 1 042 800 1 042 800 100% Ranbaxy Pharmaceuticals (Pty) Ltd MAAA0000384 V4728 PANTOCID 40MG INJECTION 10ML R22.94 1 x 1 14 10 95.00 181753528 VI
120 Paracetamol 10mg/ml, injection for IV infusion, 100ml
1 585 240 1 585 240 100% Biotech Laboratories (Pty) Ltd MAAA0029826 VUV35 PARACETAMOL BIOTECH IV R11.74 1 x 100ml 14 10 96.00 181818827 VI
122 Pethidine 25mg/ml, injection, 1ml 354 260 354 260 100% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Pethidine Inj. 25mg/1ml R4.60 1 x 10 14 400 96.00 189703124 AM
123 Pethidine 50mg/ml, injection, 1ml 1 815 320 1 452 256 80% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Pethidine Inj. 50mg/1ml R4.20 1 x 10 14 400 96.00 180076519 AM
123 Pethidine 50mg/ml, injection, 1ml 1 1 815 320 363 064 20% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 PETHIDINE HCI FRESENIUS PF 50 mg/1 ml R4.67 1 x 1 14 10 Amps 80.93 180076519 AM
124 Pethidine 50mg/ml, injection, 2ml 2 769 710 2 492 739 90% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Pethidine Inj. 100mg/2ml R4.90 1 x 10 14 400 96.00 180076540 AM
124 Pethidine 50mg/ml, injection, 2ml 1 2 769 710 276 971 10% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 PETHIDINE HCI FRESENIUS PF 100 mg/2 ml R6.21 1 x 1 14 10 Amps 66.94 180076540 AM
125 Phenylephrine 10mg, injection, 1ml
Product awarded:Phenylephrine 10mg, injection, 1ml1 pack of 5 injections
Price vs Pack size:1 x 1 injection = R67.021 x 5 injections = R335.10
637 460 637 460 100% Abbott Laboratories South Africa (Pty) Ltd MAAA0030395 V2150 Phenylephrine 10mg, injection, 1ml R67.02 1 x 5 14 1 x 5 94.00 180076556 AM
126 Phenytoin 50mg/ml, injection, 5ml 1 278 200 1 278 200 100% Ascendis Pharma (Pty) Ltd MAAA0043637 V0DM6 Phlexy 250 mg/5ml R42.48 1 x 5ml vial 14 10 vials 100.00 189708084 VI
127 Phospholipids, Total (Beractant), 100mg/4ml, 1 Vial
35 215 35 215 100% AbbVie (Pty) Ltd MAAA0076921 V3PG3 Survanta R1 631.44 1 x 4ml 14 10 91.00 181772157 VI
128 Phospholipids, Total (Beractant), 200mg/8ml, 1 Vial
17 274 17 274 100% AbbVie (Pty) Ltd MAAA0076921 V3PG3 Survanta R3 262.39 1 x 8ml 14 10 91.00 189753628 VI
129 Potassium Chloride 15%, m/v injection, 10ml
1 2 470 180 2 470 180 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 POTASSIUM CHLORIDE FRESENIUS 15 % (Flexivial)
R2.13 1 x 1 14 20 Flexivials 91.00 189710612 AM
130 Potassium Phosphate Monobasic, Anhydrous, Potassium Phosphate Dibasic Anhydrous, 1.09g/1.05g, injection, 10ml
131 090 131 090 100% Adcock Ingram Critical Care (Pty) Ltd MAAA0010153 V4222 SABAX POTASSIUM PHOSPHATE SOLUTION FOR INJECTION AFTER DILUTION
R60.38 1 x 10 14 10 100.00 180076573 AM
131 Promethazine 25mg/ml, injection, 1ml 1 691 430 691 430 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 PROMETHAZINE HCI FRESENIUS 25 mg R7.70 1 x 1 14 10 Amps 91.00 189703419 AM
132 Promethazine 25mg/ml, injection, 2ml 1 319 811 319 811 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 PROMETHAZINE HCI FRESENIUS 50 mg R8.22 1 x 1 14 10 Amps 91.00 189703420 AM
133 Propofol 10mg/ml, injection, 20ml 1 446 630 1 446 630 100% Biotech Laboratories (Pty) Ltd MAAA0029826 VUV35 MILSIA 1 % 20 ml R12.69 5 x 20ml 14 10 96.00 180076590 AM
134 Propofol 10mg/ml, injection, 50ml 195 590 195 590 100% Biotech Laboratories (Pty) Ltd MAAA0029826 VUV35 MILSIA 1 % 50 ml R37.54 1 x 50 ml 14 10 96.00 189763039 VI
136 Quinine 300mg, injection, 1ml 1 46 610 46 610 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 QUININE DIHYDROCHLORIDE FRESENIUS 300 mg/1 ml
R25.25 1 x 1 14 10 Vials 91.00 189706315 AM
137 Ranitidine 25mg/ml, injection, 2ml 822 410 822 410 100% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 CPL Alliance Ranitidine Inj. 50mg/2ml R2.95 1 x 10 14 500 96.00 180076594 AM
138 Remifentanil 2mg, injection, 5ml 47 070 47 070 100% Pharmacare Limited MAAA0008452 V2205 Fortiva 2 Inj 5x5ml R174.80 5 x 5ml 14 5 95.00 181757213 VI
139 Rocuronium 50mg, injection, 5ml 1 777 100 777 100 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 ROCURONIUM FRESENIUS 10 mg/ml (50 mg/5 ml)
R33.93 1 x 1 14 10 Vials 91.00 180960252 VI
Page 6 of 8
HP06-2021SVP: SUPPLY AND DELIVERY OF SMALL VOLUME PARENTERALS AND INSULIN DEVICES TO THE DEPARTMENT OF HEALTH
CONTRACT CIRCULARVERSION 2
FOR THE PERIOD 01 MAY 2021 TO 30 APRIL 2024
Item No Item Specification *ADD Estimate Quantity Awarded
Split Supplier Name Central Supplier Database Number
Supplier CodeV-Number
Registered Product Name Delivered Price
Pack Size Offered: Unit Pack
Lead-Time (≤ 14 calendar
days)
MOQ Total Score
National Stock Number
UOM
141 Sodium bicarbonate 4% m/v, injection, 50ml
Product awarded:Sodium bicarbonate 4% m/v, injection, 50ml1 pack of 60 bagsRemaining shelf life: 4 - 10 months
Price vs Pack size:1 x 1 bag = R58.151 x 60 bags = R3489.00
1 109 550 109 550 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 SODIUM BICARBONATE FRESENIUS 4 % INJECTION
R57.77 1 x 1 14 60 Bags 91.00 180358064 BG
142 Sodium bicarbonate 8.5% m/v, injection, 50ml
Product awarded:Sodium bicarbonate 8.5% m/v, injection, 50ml1 pack of 60 bagsRemaining shelf life: 4 - 10 months
Price vs Pack size:1 x 1 bag = R73.821 x 60 bags = R4429.20
1 578 010 578 010 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 SODIUM BICARBONATE FRESENIUS 8.5 % INJECTION
R73.33 1 x 1 14 60 Bags 91.00 180358068 BG
143 Sodium chloride 0.9% m/v, injection, 10ml 12 400 540 11 160 486 90% B Braun Medical (Pty) Ltd MAAA0040832 VYL89 0.9% Sodium Chloride Injection B. Braun (10ml) (Product Code: 3659990)
R1.48 1 x 1 14 100 96.00 189700088 AM
143 Sodium chloride 0.9% m/v, injection, 10ml 12 400 540 1 240 054 10% Adcock Ingram Critical Care (Pty) Ltd MAAA0010153 V4222 SODIUM CHLORIDE 0.9% ADCO R2.30 1 x 100 14 100 50.14 189700088 AM
144 Somatropin 15iu, powder for injection, cartridge + diluent
23 720 23 720 100% Novo Nordisk (Pty) Ltd MAAA0013414 V2743 NORDITROPIN NORDILET 5 MG R536.07 1 x 1 14 1 92.00 181808985 EA
145 Somatropin 30iu, powder for injection, cartridge + diluent
24 895 24 895 100% Sandoz SA (Pty) Ltd MAAA0011663 VVZ69 Omnitrope 10mg R1 016.00 1 x 1 14 100 91.00 181799365 EA
147 Streptokinase 1.5MU injection 10 155 10 155 100% Actor Pharma (Pty) Ltd MAAA0183044 V2G28 Fibreaker R4 640.80 1 x 1 14 5 90.00 189711674 VI
148 Suxamethonium 50mg/ml, injection, 2ml
Product awarded:Suxamethonium 50mg/ml, injection, 2mlRemaining shelf life: 4 - 10 months
1 635 010 635 010 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 SUXAMETHONIUM CHLORIDE-FRESENIUS 100 mg/2 ml
R12.71 1 x 1 14 10 x Amps 91.00 180076785 AM
152 Tranexamic Acid 100mg/ml, injection, 5ml
Product awarded:Tranexamic Acid 100mg/ml, injection, 5ml1 pack of 5 injections
Price vs Pack size:1 x 1 injection = R37.601 x 5 injections = R188.00
1 734 980 1 734 980 100% Pfizer Laboratories (Pty) Ltd MAAA0019202 V2189 Cyklokapron IV 500 R37.60 1 x 5 14 5 91.00 180076981 AM
153 Vecuronium 4mg, injection, 2ml 53 840 53 840 100% Ranbaxy Pharmaceuticals (Pty) Ltd MAAA0000384 V4728 MUSCURON R45.94 1 x 1 14 5 95.00 222000188 EA
154 Verapamil HCl 2.5mg/ml, injection, 2ml 17 910 17 910 100% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Verapmil Inj. 5mg/2ml R7.20 1 x 10 14 100 96.00 180076998 AM
156 Vitamin B1 (Thiamine) 100mg/ml, injection, 10ml
412 200 412 200 100% Litha Pharma (Pty) Ltd (Acino Pharma) MAAA0009244 VGS73 LITHA THIAMINE INJECTION R37.56 1 x 10 14 1 x 10 100.00 189700006 VI
157 Vitamin B12 (Cyanocobalamin) 1000mcg, injection, 1ml
487 350 487 350 100% P & G South African Trading (Pty) Ltd MAAA0913191 VJDY7 Neurobion Ampoules R48.84 3 x 3ml 14 30 91.00 189715773 AM
Page 7 of 8
HP06-2021SVP: SUPPLY AND DELIVERY OF SMALL VOLUME PARENTERALS AND INSULIN DEVICES TO THE DEPARTMENT OF HEALTH
CONTRACT CIRCULARVERSION 2
FOR THE PERIOD 01 MAY 2021 TO 30 APRIL 2024
Item No Item Specification *ADD Estimate Quantity Awarded
Split Supplier Name Central Supplier Database Number
Supplier CodeV-Number
Registered Product Name Delivered Price
Pack Size Offered: Unit Pack
Lead-Time (≤ 14 calendar
days)
MOQ Total Score
National Stock Number
UOM
158 Vitamin K1 (Phytomenadione) 10mg/1ml, injection
773 990 773 990 100% Pharmaco Distribution (Pty) Ltd MAAA0044115 VBVW1 KONAKION R22.35 1 x 10 14 10 90.00 180146851 AM
159 Vitamin K1 (Phytomenadione) 2mg/0.2ml, injection
3 500 390 3 500 390 100% Pharmaco Distribution (Pty) Ltd MAAA0044115 VBVW1 KONAKION R13.04 1 x 5 14 5 90.00 180953330 AM
160 Water for injection BP, injection, 10ml 37 241 680 37 241 680 100% B Braun Medical (Pty) Ltd MAAA0040832 VYL89 Water for Injections B. Braun 10ml (Product Code: 3659980)
R1.27 1 x 1 14 100 96.00 189710871 AM
161 Water for injection BP, injection, 20ml 1 4 112 500 4 112 500 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 WATER FOR INJECTIONS FRESENIUS "FLEXIVIAL" 20 ml
R2.67 1 x 1 14 20 Flexivials 91.00 189710862 AM
162 Zuclopenthixol acetate 50mg, injection, 1ml 228 680 228 680 100% Lundbeck SA (Pty) Ltd MAAA0031052 VVS90 Clopixol Acuphase 50 mg/ml R94.90 1 x 1 14 5 90.00 189753243 AM
163 Zuclopenthixol decanoate 200mg/ml, injection, 1ml
2 142 750 2 142 750 100% Lundbeck SA (Pty) Ltd MAAA0031052 VVS90 Clopixol Depot 200mg/ml R49.82 1 x 1 14 5 90.00 180057631 AM
* ADDENDUM 1
AM Ampoule
BG Bag
BX Box
CA Cartridge
EA Each
SG Syringe
VI Vial
LEGEND UNIT OF MEASUE (UOM)
Page 8 of 8
S
PLEAS
SPE
SUPPLY AN
DEVIC
SE NOTE:
ECIAL REQ
ND DELIVE
CES TO TH
B
C
AN ERRA
NO
QUIREMEN
H
ERY OF SM
HE DEPAR
01 MAY 2
BID VALID
CLOSING D
24 JU
TUM WILL
TO 28
O BRIEFING
TS AND C
HP06-2021
MALL VOLU
RTMENT O
2021 TO 30
DITY PERIO
DATE AND
ULY 2020 A
L BE PUBL
8 SEPTEMB
G SESSION
ONDITION
SVP
UME PARE
F HEALTH
0 APRIL 20
OD: 120 DA
D TIME OF
AT 11H00
ISHED TO
BER 2020
N WILL BE
NS OF CON
ENTERALS
H FOR THE
024
AYS
BID:
AMEND T
HELD.
NTRACT
S AND INS
PERIOD
THE CLOSI
ULIN
ING DATE
TABLE1. LEGIS10. LATE11. COUN12. FRON13. SUPP14. COM15. CONT16. CONT17. PART18. REGI19. POST2. BID IN20. AWA21 NEGO22. NON-23. PRIC23.1 ELIG23.2 PRIC23.3 APP23.4 ROU23.5 EXC23.6 PRIC24. QUAL25. DELIV26. SUPP27. PACK28 SHEL29. CEDI3. EVALU3.1 PHAS3.1.1 LEG3.1.2 RES3.1.3 BID3.1.4 AUT3.1.5 TAX30. THIR4. PHASE4.2 COM5. PHASE6. PREFE7. VALUE8. SUBM9. COMPABBREVBID DOCSECTIONSECTIONSECTION
S
OF CONTENSLATIVE AND E BIDS ............NTER CONDITNTING ............PLIER DUE DILMUNICATION TACT DETAILSTRACT PERIOTICIPATING AUISTRATION ONT AWARD PAR
NFORMATION SARD CONDITIOOTIATIONS .....-COMMITMENT
CE REVIEW .....GIBILITY RELACE ADJUSTME
PLICATION FOUTINE PRICE ACEPTIONAL PRCE ADJUSTMELITY ..............VERY AND QUPLIER PERFORKAGING, LABE
LF LIFE ...........ING, MERGERSUATION CRITESE II: MANDATGISLATIVE RESPONSIVE BID
D RESPONSE DTHORISATIONX COMPLIANC
RD PARTIES ...E III: PRODUCTPLIANCE WITHE IV: PREFEREERENCE FOR E ADDED TAX
MISSION OF BIDPLETION OF DOVIATIONS .......CUMENT CHECN A ................N B ................N C ................
Special Requ
NTS REGULATORY......................
TIONS ...................................
LIGENCE ..............................S ....................
OD ...................UTORITIES ANN DATABASESRTICIPATION ..SESSION ........NS .......................................T ..........................................
ATING TO RATENTS RELATINR CONTRACT
ADJUSTMENTSRICE ADJUSTMENTS BASED O......................
UANTITIES ......RMANCE MANELLING AND B......................S, TAKE OVERERIA ...............TORY REQUIREEQUIREMENTSDS ..................DOCUMENT ....N DECLARATIOCE STATUS ...........................T TECHNICAL H SPECIFICATENCE POINT SLOCALLY PRO......................DS ..................OCUMENTS AN......................
CK LIST ............................................................................
uirements an
Y FRAMEWOR.................................................................................................................................................................
ND OTHER HEAS OF PARTICIP..........................................................................................................................................
TE OF EXCHANNG TO FOREIGUAL PRICE ADS ....................MENTS ............ON A SYSTEM..............................................AGEMENT......
BARCODES ............................RS AND CHANG.......................EMENTS .........
S TO THIS BID ...............................................ON ................................................................ COMPLIANCE
TIONS .............SYSTEM ..........ODUCED PROD..............................................ND BID SUBMI...................................................................................................................
nd Conditions
K .............................................................................................................................................................................ALTH ESTABLPATING AUTHO....................................................................................................................................
NGE ADJUSTMGN EXCHANGEDJUSTMENTS ............................................ATIC REVIEW ..............................................................................................................GES IN SUPPL................................................................................................................................................................................E ................................................................DUCTS .......................................................ISSION .........................................................................................................................
s of Contract
......................
......................
......................
......................
......................
......................
......................
......................IHSMENT .......
ORITIES ..............................................................................................................................................
MENTS ............E RISK ..................................................................................................................................................................................................................
LIER DETAILS .........................................................................................................................................................................................................................................................................................................................................................................................................................................................
: HP06-2021
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
.......................
SVP
Page 2 o
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
of 38
.................. 7
................ 18
................ 19
................ 19
................ 19
................ 19
................ 20
................ 21
................ 21
................ 21
................ 22
.................. 7
................ 22
................ 25
................ 25
................ 25
................ 26
................ 26
................ 27
................ 28
................ 28
................ 29
................ 29
................ 30
................ 31
................ 35
................ 37
................ 37
.................. 7
.................. 8
.................. 8
.................. 9
.................. 9
.................. 9
................ 10
................ 38
................ 11
................ 13
................ 13
................ 14
................ 15
................ 15
................ 17
.................. 3
.................. 4
.................. 7
................ 21
................ 31
ABBRE
API
BAC
B-BBEE
CPA
CSD
EAN
EME
GMP
MCC
MHPL
MPC
NDoH
PPPFA
QSE
RoE
SAHPRA
SARS
SBD
VAT
S
EVIATIONS
: Ac
: Bi
: Br
: Co
: Ce
: Eu
: Ex
: Go
: M
: M
: M
: Na
: Pre
: Qu
: Ra
A : So
: So
: St
: Va
Special Requ
ctive Pharmac
d Adjudication
road-Based Bl
ontract Price A
entral Supplier
uropean Article
xempted Micro
ood Manufactu
edicines Cont
aster Health P
aster Procurem
ational Depart
eferential Proc
ualifying Smal
ate of Exchang
outh African H
outh African Re
tandard Biddin
alue- Added T
uirements an
ceutical Ingred
n Committee
lack Economic
Adjustment
r Database
e Numbering
o Enterprise
uring Practice
rol Council
Products List
ment Catalogu
tment of Health
curement Polic
ll Enterprise
ge
Health Products
evenue Servic
ng Document
Tax
nd Conditions
ient
c Empowerme
ue
h
cy Framework
s Regulatory A
ce
s of Contract
ent
k Act
Authority
: HP06-2021SVP
Page 3 oof 38
BID DO
All bid d
below an
Submiss
All bid d
Bidders
evaluatio
CompilaSequen
1
2
3
4
5
6
7
8
9
10
11
12
S
OCUMENT CH
documents list
nd the annexu
sion of bid doc
documents m
not complying
on
ation nce
AdmCod
CL
BSR
BFI
PBD4
SBD5
TCP
CSD
SBD
PBD
SBD
SBD
BBBE
Special Requ
HECK LIST
ted below mus
ure attached.
cuments is com
must be signed
g to any of the
min de
Docum
L Coverin
RA Bid Sign
I Bid/File
4.1 PBD 4.1
5.1 SBD 1:
P Tax Cle
D CSD Relatest ansumma
D4 SBD 4:
D9 PBD9: Dgender
D5 SBD5: TProgram
D6 SBD 6(1BBEE)
EE Valid B-originapoints
uirements an
st be sorted, f
mpulsory, unle
d.
e requirements
ent Name
ng Letter
nature. Resolu
Index
1: Contact Det
Invitation to b
earance Pin Iss
egistration repnd complete reary report will
Declaration of
Directors: Cateand disability
The National Imme
1): Preference
-BBEE certifical) or Sworn Af
nd Conditions
filed and subm
ess it's not app
s may deeme
ution/Authority
tails of Bidder
id
sued
port - A certifiedeport. Note: l not be accep
f interest
egorisation by
ndustrial Parti
e Points Claim
ate(certified cffidavit to claim
s of Contract
mitted in the e
plicable and ind
d to be non-re
y to sign bid
d copy of CSD pted.
y race,
cipation
ed (B-
copy of the m preference
: HP06-2021
exact compila
dicated as suc
esponsive and
N/A Yes
SVP
Page 4 o
ation sequence
ch in the "N/A"
d will not be c
No
of 38
eas indicated
" column.
onsidered for
Remark
CompilaSequen
13
14
15
16
17
18
19
20
21
22
23
24
S
ation nce
AdmCod
SBD
SBD
PBD
PBD1
PBD1
PBD
PBD
CIPC
NC
LICM
LICM
MRC
Special Requ
min de
Docum
D8 SBD 8:
D9 SBD 9: Determi
D1 PBD1: ANote: Nauthorismay inv
1.1 PBD 1.1third pa
1.2 PBD 1.2from the
D5 PBD5: GDeclara
D8 PBD 8: of Conta
C CIPC/Cownershregistra
C Proof ofchanges
MI Licenceof the bCertifie
M Licenceannexurlisted onCertified
C Medicinall the aCertifiedNote: Abidder be sort
uirements an
ent Name
Declaration of
Certificate of ination
Authorisation Don-compliance
sation declaratvalidate the bid1: List of produrty
2: Unconditione third party.
Good Manufacation of complia
Special Requact. Declaratio
CIPRO or proofhip/shareholdition certificatef company ceds
e to manufactuidder), includ
ed copies req
e to manufactures for local mn the MRC of td copies requi
ne Registrationassociated cond copies
All MRC's muswith the releved and filed i
nd Conditions
f Past SCM Pr
Independent B
Declaration e to submissiotion, where apd. ucts offered so
nal written und
cturing Practicance.
irements and on of complian
f of ng. Certified c
es dings, mergers
ure or import (iing all annexuired.
ure medicines,manufacturinthe bidder (apred.
n Certificates (nditions of regi
st be marked vant item numn numerical o
s of Contract
ractices
Bid
on of a valid pplicable,
ourced from
ertaking
ce (GMP).
Conditions nce.
copies of
s and name
n the name ures.
including all g sites as
pplicant).
(MRC) with istration -
by the mber and order.
: HP06-2021
N/A Yes
SVP
Page 5 o
No
of 38
Remark
CompilaSequen
25
26
27
28
A
Submis
The bid
be com
“Set 3: E
S
ation nce
AdmCod
PI
PS
BL
PRIC
All bid docume
ssion of suppo
d document
mpleted by a
Electronic ve
Special Requ
min de
Docum
Originaldetailingthe MedSouth AAuthoritNote: Aitem numin nume
S Proof of
Bidder`s
CE Signed If the Exnot signnot be c
ents listed abo
orting bid docu
check list is
all bidders a
ersion of bid d
uirements an
ent Name
l Package Inseg professionaldicines ControAfrican Health ty (SAHPRA) f
All PI`s must bember and be serical order.
f sample subm
s item list (Lis
Excel Bid Resxcel Bid responed in the spacconsidered for
ove must be so
uments is com
s available a
nd be subm
documents"
nd Conditions
ert (PI) or docu information a
ol Council (MCProducts Regfor each produe marked with sorted and file
mission
st of products o
sponse Pricingonse Pricing Scce provided, thr evaluation.
orted, filed and
mpulsory, unlescolumn
as Annexure
mitted in hard
s of Contract
ument pproved by C) or the ulatory
uct offered. the relevant d/submitted
offered)
g Schedule chedule is he bid will
d submitted in
ss it's not appln
e A in an exc
d copy and
: HP06-2021
N/A Yes
the exact orde
icable and ind
cel spreadsh
as part of th
SVP
Page 6 o
No
er as indicated
dicated as such
heet format
he electroni
of 38
Remark
d above
h in the "N/A"
and should
c copies of
SECTIO 1. LEG
This
(Act
(Act
in te
are
Con
2. BID
As t
200
It is
allow
3. EVA
The
Ph
Mareq
Coand
S
ON A
GISLATIVE A
s bid and all co
t 101 of 1965)
t 194 of 1993)
erms of the Pu
supplementar
ntract are in co
D INFORMAT
the National D
2, published in
strongly reco
w the respons
ALUATION C
e evaluation pr
hase I
andatory and quirements
ompliance withd other bid req
Special Requ
AND REGUL
ontracts eman
, Pharmacy Ac
; General Con
ublic Finance M
ry to General C
onflict with the
TION SESSIO
Department of
n the Gazette
ommended tha
se to reach the
CRITERIA
rocess will be c
other bid
h mandatory quirements
uirements an
LATORY FRA
nating there fro
ct, (Act 53 of 1
nditions of Con
Management A
Conditions of C
General Cond
ON
Health complie
18 March 202
at all prospect
e bidders befor
conducted in p
Phase II
Product teccompliance
Compliance specificationTest reports sample evalu
nd Conditions
AMEWORK
om will be subj
1974); Patents
ntract issued in
Act, 1999 (Act
Contract (GCC
ditions of Cont
es with the reg
20 no briefing s
ive bidders su
re the tender c
phases as follo
chnical
with technical s received fromuation
s of Contract
ject to the Med
s Act, 1978 (Ac
n accordance
1 of 1999). Th
C). Where, how
tract, the Spec
gulations mad
session or pu
ubmit all enqui
closes.
ows:
Phase III
Price andB-BBEE
m
Bids evaluterms of thpreference
: HP06-2021
dicines and Re
ct 57 of 1978)
with Treasury
he Special Co
wever, the Spe
cial Conditions
e under the D
blic bid openin
ries to tenders
P
d Ran
uated in he 90/10 e system
Ran
SVP
Page 7 o
elated Substa
; Trade Marks
Regulation 16
onditions of Co
ecial Condition
s of Contract p
isaster Manag
ng will be held
hase IV
Recommendatnd Award
Recommendatind award
of 38
nces Act,
s Act, 1993
6A published
ontract (SCC)
ns of
prevail.
gement Act,
d.
.za on time to
tion
on
3.1
3.1.
S
PHASE I:
Bidders mu
and time of
documents
comply wit
.1 LEGISLA
Items offer
1965 (Act 1
contract.
A certified
the Medicin
items offer
The bidder
The bidder
in terms of
including a
the produc
The bidder
medicines,
also be the
Where an i
Related Su
Bidders mu
Marks Act,
Special Requ
MANDATOR
ust submit all r
f the bid. Durin
s submitted un
h all mandator
ATIVE REQUI
red must be re
101 of 1965),
d copy of the o
nes and Relat
ed.
r must be indic
r offering a pro
f section 22C (
all annexures.
ct.
r offering a pro
, including all a
e applicant.
item offered is
ubstances Act
ust comply wit
1993 (Act 194
uirements an
RY REQUIRE
required docum
ng this evalua
nder mandator
ry requiremen
IREMENTS T
egistered in ter
and must com
original Medici
ed Substance
cated as the ap
oduct must be
(1) (b) of the M
A certified co
oduct must sub
annexures for
s not eligible fo
, 1965 (Act 10
th the requirem
4 of 1993). Wh
nd Conditions
EMENTS
ments indicate
tion phase, bid
ry requirement
ts will be disqu
TO THIS BID
rms of section
mply with the co
ine Registratio
es Act, 1965 (A
pplicant on the
the holder of a
Medicines and
opy of the orig
bmit a certifie
local manufac
or registeration
01 of 1965), a p
ments of the P
here applicabl
s of Contract
ed above with
dder’s respons
ts. This phase
ualified.
D
15 of the Med
onditions of re
on Certificate,
Act 101 of 196
e Medicines R
a licence to m
Related Subs
ginal licence m
ed copy of the
cturing sites lis
n in terms of s
package inser
atents Act, 19
e, an explana
: HP06-2021
the bid docum
ses will be eva
is not scored
dicines and Re
egistration for t
issued in term
5), must be in
Registration Ce
anufacture or
stances Act, 19
must be submit
original licen
sted on the MR
ection 15(3) (a
rt of the item m
978 (Act 57 of
tion for any no
SVP
Page 8 o
ments at the cl
aluated based
and bidders w
elated Substan
the duration of
ms of section 1
cluded with th
ertificate.
import medici
965 (Act 101 o
tted by the bid
ce to manufac
RC of the bidd
a) of the Medic
must be supplie
1978) and the
on-compliance
of 38
osing date
on the
who fail to
nces Act,
f the
5(3) (a) of
he bid for all
ines issued
of 1965)
dder offering
cture
der who must
cines and
ed.
e Trade
e must be
3.1.
3.1.
3.1.
S
provided. I
holder of s
patent hold
.2 RESPONS
Bidders are
All prices
bid docume
Response
.3 BID DOCU
Bidders ar
and item q
The excel b
disability p
without cha
The prices
All prices
The bid pri
specificatio
Prices sub
VAT.
.4 AUTHOR
Only the ho
Substance
Special Requ
n the case wh
uch a product
der must be su
SIVE BIDS
e required to s
must be subm
ent. In this reg
Document” ex
UMENTS
e required to
uestionnaires.
bid response d
rovided forms
anging the stru
quoted must
must be subm
ce offered for
on and the unit
mitted must no
ISATION DE
older of a Med
s Act, 1965 (A
uirements an
here a product
, a letter autho
ubmitted with t
submit respons
mitted with 2
gard, bidder’s a
xplaining the d
submit respo
.
documents i.e
an integral pa
ucture thereof
be furnished a
mitted with tw
a product is d
t specified.
ot exceed the
ECLARATION
dicines Registr
Act 101 of 196
nd Conditions
is manufactur
orising the ma
the bid.
sive bids by co
(two) decima
attention is dra
different fields
nsive bids by
e. pricing sched
art of the bid d
. All pages mu
as all inclusive
wo (2) decima
deemed to be f
ex-manufactu
N
ration Certifica
5), may subm
s of Contract
red under a vo
rketing of the
ompleting all t
als. Documen
awn to the doc
in the bid docu
completing a
dule and Direc
ocument and
ust be signed.
e (incl. VAT) on
als.
for the pack si
urer componen
ate issued in te
it a bid.
: HP06-2021
oluntary licens
product, provi
he prices in th
nt and respons
cument “Defin
ument.
all the prices,
ctors: Categor
bidders must
n the basis of
ze as advertis
nt of the Single
erms of the Me
SVP
Page 9 o
e issued by th
ded to the bid
he Excel Bid R
se fields in the
ition of fields i
mandatory res
risation of race
ensure that it
supply and de
sed in the item
e Exit Price inc
edicines and R
of 38
he patent
der by the
Response.
e fillible PDF
n the Bid
sponse fields
e, gender and
is completed
elivery.
m
clusive of
Related
3.1.
S
In the even
external th
mutually ag
Where a th
Authorisati
The Nation
the Authori
Departmen
Failure to s
accordance
No agreem
Health.
.5 TAX COM
The Centra
the tax com
Certificates
Tax Cleara
It is a cond
satisfactory
It is a requ
an on-goin
submitting
Bidders are
their bid th
the supplie
Special Requ
nt that the Man
ird parties, the
greed upon be
hird party is inv
on Declaration
nal Departmen
isation Declara
nt of Health wi
submit a duly c
e with the abo
ment between t
MPLIANCE S
al Supplier Dat
mpliance statu
s anymore bu
ance Certificat
dition of this bid
y arrangement
irement that b
g basis during
this bid, such
e required to b
heir Master Re
er's tax status o
uirements an
nufacturer, Pa
e bidder must
etween the bid
volved in any c
n (PBD1) for e
nt of Health res
ation and, sho
ll exercise any
completed and
ove provisions,
the bidder and
STATUS
tabase and th
s of a bidder.
ut has introduc
tes which they
d that the tax m
ts have been m
idders grant a
g the tenure of
confirmation i
be registered o
egistration Nu
on the Centra
nd Conditions
cker or other e
ensure that al
dder and these
capacity, the b
each such third
serves the righ
ould the inform
y of the remed
d signed Autho
, will invalidate
d any third par
e tax complian
The South Afr
ced an online
y can submit w
matters of the
made with SA
a written confir
f the contract,
is deemed to h
on the Govern
umber (Supp
l Supplier Data
s of Contract
entity, as listed
l legal, financi
e third parties.
bidder must su
d party.
ht to verify any
mation be found
dies available t
orisation Decla
e the bid for su
rty will be bind
nce status PIN
rican Revenue
provision via
with their bids o
bidder be in o
ARS to meet th
mation when s
disclose the b
have been gra
nment's Centr
lier Number)
abase;.
: HP06-2021
d on the certifi
al and supply
ubmit a duly co
y information s
d to be false o
to it in the bid
aration, with th
uch goods or s
ing on the Nat
N are the appr
e Service doe
eFiling, for bid
or price quota
order at any po
he bidder’s tax
submitting this
bidder’s tax co
anted.
ral Supplier D
in order to ena
SVP
Page 10 o
icate of registr
arrangements
ompleted and
supplied by the
or incorrect, the
documents.
he required an
services offere
tional Departm
roved methods
s not issue Ta
dders to print
tions.
oint in time, or
obligations.
s bid that SAR
mpliance statu
Database and
able the institu
of 38
ration are
s have been
signed
e bidder in
e National
nnexure(s), in
ed.
ment of
s of verifying
ax Clearance
their own
r that
RS may, on
us and, by
to include in
ution to verify
4. PHA 4.1 SAM
All b
Dep
Fail
Sam
time
S
Foreign su
Africa mus
been made
Revenue S
Service wil
foreign ent
Should the
wull reject
The Nation
Where con
Supplier D
Bidders rem
this bid.
ASE II: PRO
MPLES TO B
bidders are req
partment of He
Compliance w
Compliance o
101 of 1965)
ure to submit
mples are requ
e of bid:
Special Requ
uppliers with
t complete th
e to a foreign b
Service to ema
ll issue a confi
tity has tax obl
e recommende
the bid submit
nal Departmen
nsortia/joint ve
atabase and t
main responsi
DUCT TECH
BE SUBMITT
quired to subm
ealth with prod
with specificat
of the product
.
samples at bo
uired to be sub
uirements an
neither South
he questionnai
bidder, the ND
ail address: G
irmation of tax
ligations in So
ed bidder fail t
tted by the bid
nt of Health sh
ntures/sub-co
heir tax compl
ble to update
HNICAL COM
TED TO HEA
mit samples, in
ducts to confirm
tions as set ou
t with the requ
oth health esta
bmitted to each
nd Conditions
h African tax
ire on the SB
DOH will subm
overnmentlnst
x obligations le
outh Africa
to provide writ
dder.
all verify the b
ntractors are i
liance status w
their CSD info
MPLIANCE
ALTH ESTAB
ncluding bidde
m the following
ut in the bid do
uirements of th
ablishments lis
h (both) of the
s of Contract
obligations n
D1. Where a
mit the bidder's
etter to the ND
ten proof of th
bidder’s tax co
nvolved, each
will be verified
ormation in line
BLISHMENTS
ers who are cu
g:
ocument/item s
he Medicines
sted below will
e addresses ind
: HP06-2021
nor history of
recommendat
s completed S
ov.za. The So
OH, confirmin
heir tax complia
mpliance statu
h party must be
through the C
e with the bid d
S
rrently supplyi
specification.
and Related S
invalidate the
dicated below
SVP
Page 11 o
doing busine
tion for award
BD1 to the So
uth African Re
ng whether or n
ance status, th
us through the
e registered o
Central Supplie
documents su
ing the Nation
Substances A
e bid for such it
prior to closin
of 38
ess in South
d of a bid has
outh African
evenue
not the
he NDOH
e CSD.
n the Central
er Database.
ubmitted for
al
Act, 1965 (Act
tems offered.
ng date and
Mr D
Dep
Tel:
Gau
Stor
35 P
Hurs
209
S
Dumisani Male
pot Manager
011 628 9131
uteng: Medical
re 3
Plunkett Avenu
st Hill
2
No samp
Samples
address.
Bidders
It is the
provided
All samp
All samp
All samp
approved
Proof of
evaluatio
Special Requ
ele
1
l Supplies Dep
ue
ples must be s
s must be ma
.
must submit a
responsibility
d above.
ples for awarde
ples must be a
ples submitted
d by the MCC
f sample sub
on site, must b
uirements an
pot
sent to the Nat
arked with the
at least one ori
y of the bidde
ed items will b
true represen
d must include
or SAHPRA.
mission, inclu
be submitted w
nd Conditions
tional Departm
e bid number,
iginal pack of e
er to ensure
e retained for
ntation of the p
e the package
uding a signe
with the bid do
s of Contract
Mr Nisaar M
Pharmaceut
Tel: 021 483
Western Ca
4th Floor, Ca
16 Chiappin
Cape Town
8001
ment of Health.
the item num
each offer for
that samples
the period of t
product which
insert or doc
ed copy of th
cuments at the
: HP06-2021
Mia
tical Policy Sp
3 5800
pe: Departme
ape Medical D
i Street
.
mber as well
evaluation.
have been r
the contract.
will be supplie
cument detailin
e item list as
e closing date
SVP
Page 12 o
ecialist
nt of Health
Depot
as the bidder
received at th
ed.
ng professiona
s received by
e and time of th
of 38
r’s name and
he addresses
al information
y the sample
he bid.
4.2 CO
Item 5. PHA 5.1 A M
5.2 PO
In te
awa
B-BCon
1
2
3
4
5
6
7
8
Non
For
S
MPLIANCE W
ms must compl
ASE IV: PRE
MAXIMUM OF
180Ps
Where Ps = Pt = Pmin =
INTS AWAR
erms of Regula
arded to a bidd
BEE Status Lentributor
-compliant cont
this tender, th
Special Requ
WITH SPEC
ly with the spe
EFERENCE P
F 80 OR 90 P
80/20
min
mi
P
PPt
Points scPrice of bPrice of l
RDED FOR B
ation 6(2) and
der for attainin
evel of
tributor
e 90/10 prefere
uirements an
IFICATIONS
ecification as d
POINT SYST
POINTS IS A
in
or
cored for pricebid under conslowest accepta
-BBEE STAT
7(2) of the Pr
g the B-BBEE
Number(90/10 sy
ence point sys
nd Conditions
S
detailed in the
TEM
ALLOCATED
or
90Ps
e of bid under csideration able bid
TUS LEVEL
referential Pro
E status level o
r of points ystem)
10
9
6
5
4
3
2
1
0
stem will be ap
s of Contract
bid document
D FOR PRICE
90/
m10
P
PPt
consideration
OF CONTRI
curement Reg
of contribution
plied.
: HP06-2021
t.
E ON THE FO
10
min
minP
BUTOR
gulations, prefe
in accordance
Number o(80/20 sys
SVP
Page 13 o
OLLOWING B
erence points
e with the table
of points stem)
20
18
14
12
8
6
4
2
0
of 38
BASIS:
must be
e below:
B
t
t
T
s
O
s
a
o
E
A
S
p
I
p
N
s
t
c
A
n
6. PRE
The
requ
In o
limit
med
prod
S
Bidders are re
the original B-
the B-BBEE st
The points sc
scored for pric
Only bidders w
submitted a c
accounting off
or an accredite
Exempted Mic
Affidavit as pre
Sworn Affidav
prescribed by
If the bidder f
preference po
National Depa
substantiate c
the nearest tw
contract will be
A contract ma
number of poin
EFERENCE
e National Dep
uired to indica
order to provide
ted to product
dicines (includ
duction of finis
Special Requ
equired to com
BBEE status l
tatus level poi
cored by a bid
ce.
who have com
certified copy
ficer (as conte
ed verification
cro Enterprise
escribed by th
vits submitted
the B-BBEE C
fails to compl
oints for B-BB
artment of H
claims it has m
wo (2) decima
e awarded to t
ay, on reasona
nts.
FOR LOCAL
partment of He
te on the Exce
e preference t
formulation an
ing importatio
shed products)
uirements an
mplete the pre
evel verificatio
nt.
dder in respec
mpleted and sig
of an origina
mplated in se
agency will be
es (EME’s) a
e B-BBEE Co
by EME’s an
Commission.
ly with the pa
BEE status lev
ealth may, b
made with rega
als. In the eve
the bidder sco
able and justif
LLY PRODU
ealth reserves
el Bid Respons
o locally produ
nd conversion
n of raw mate
) in the Repub
nd Conditions
eference claim
on certificate,
ct of the leve
gned the decla
al B-BBEE st
ction 60(4) of
e considered f
and Qualifying
ommssion, Pra
nd QSE will s
aragraphs abo
vel of contribu
before a bid
ard to prefere
ent that two (
oring the highe
fiable grounds
CED PRODU
the right to co
se Document
uced products
n processes th
rial of active p
blic of South Af
s of Contract
m form (SBD 6
at the closing
l of B-BBEE
aration part of
tatus level ce
the Close Cor
for preference
g Small Ente
actice Guide 01
strictly be eva
ove, the bidde
ution and will
is adjudicated
nce claimed.
(2) or more b
est number of p
s, be awarded
UCTS
onsider locally
where the pro
s, the definition
at use materia
pharmaceutica
frica.
: HP06-2021
6.1), and subm
date and time
contribution w
the preference
ertificate issue
rporation Act,
e points.
rprices (QSE
1 of 2019.
aluated accord
er will be dee
therefore be
d or at any
The points sc
bids have sco
preference po
d to a bid that
produced prod
oducts are man
n of a locally p
als and compo
al ingredients (A
SVP
Page 14 o
mit a valid cer
e of the bid in o
will be added
e claim form a
d by a regist
1984 (Act No.
’s) must sub
ding the the g
emed not to h
allocated a z
time, require
cored will be ro
red equal tota
ints for B-BBE
t did not score
ducts offered.
nufactured.
roduced produ
onents to manu
API) and of ex
of 38
rtified copy of
order to claim
to the points
and who have
tered auditor,
. 69 of 1984))
mit a Sworn
guidelines as
have claimed
zero (0). The
a bidder to
ounded off to
al points, the
EE.
e the highest
Bidders are
uct will be
ufacture
xcipients for
Whe
item
neg
Bids
7. VAL
All
bid
8. SUB
All b
indic
Sub
in th
All b
S
ere the Nation
ms will be alloc
gatively impac
s for products
The South A
primary site o
The bidder o
terms of sect
all annexures
The bidder of
including all a
applicant.
The referenc
The site/s of
Demonstrate
Excel Bid Re
Previous sup
Compliance t
LUE ADDED
bid prices mu
d.
BMISSION O
bid documents
cated below a
bmission of bid
he Bid Docume
bid documen
Special Requ
nal Departmen
cated and awa
ct upon secu
that qualify fo
African Health
of production a
ffering a prod
tion 22C (1) (b
s. A certified
ffering a produ
annexures for
e price as pub
manufacture a
d capacity to
sponse Docum
pplier performa
to all other asp
D TAX
st be inclusive
OF BIDS
s listed below m
and the annexu
d documents is
ent Check List
nts must be si
uirements an
t of Health giv
arded proportio
rity of supply
r this preferen
h Product Aut
as one that is l
uct must be th
b) of the Medic
copy of the o
uct must subm
r local manufa
blished by Nat
and/or packag
service the re
ment;
ance;
pects containe
e of 15% Value
must be sorted
ure attached.
s mandatory, u
t.
igned.
nd Conditions
ves preference
onately to loca
y and affordab
nce must comp
thority (SAHP
located in the
he holder of a
cines and Rela
original licence
mit a certified
acturing sites l
ional Departm
ging for the pro
equired volum
ed in these Sp
e-Added Tax.
d, filed and su
unless it's not
s of Contract
e to locally pro
ally produced p
bility.
ply with all of t
RA) certificate
Republic of S
licence to ma
ated Substanc
e must be subm
copy of the or
isted on the M
ment of Health
oduct offered is
mes as evaluat
ecial Conditio
Failure to com
ubmitted in the
applicable and
: HP06-2021
duced produc
products, prov
he following c
e of registrati
outh Africa;
anufacture or
ces Act, 1965
mitted by the b
riginal licence
MRC of the bid
has not been
s located in So
ted in terms o
ns of Contract
mply with this c
e exact compila
d indicated as
SVP
Page 15 o
cts, the quantit
ided this does
riteria:
ion for a prod
import medicin
(Act 101 of 19
bidder offering
to manufactur
dder who mus
exceeded (if a
outh Africa;
of the data pro
t
condition will in
ation sequenc
such in the "N
of 38
ies for these
s not
duct lists the
nes issued in
965) including
the product.
re medicines,
st also be the
applicable);
ovided in the
nvalidate the
ce as
N/A" column
Bidd
con
S
ders not com
sidered for ev
Covering Lett
Status relatin
Resolution/A
Bid/File Index
PBD 4.1: Con
SBD 1: Invita
Tax Clearanc
CSD Registra
be accepted;
SBD 4: Decla
PBD9: Direct
SBD5: The N
SBD 6(1): Pr
Valid B-BBEE
SBD 8: Decla
SBD 9: Certif
PBD1: Autho
where applica
PBD 1.1: List
PBD 1.2: Unc
PBD5: Good
PBD 8: Spec
CIPC/CIPRO
Proof of com
Certified copy
Certified copy
listed on the
Special Requ
plying to any
aluation.
ter i.e. limited
ng to TAX, B-B
uthority to sign
x;
ntact Details o
ation to bid;
ce Pin Issued;
ation report - A
aration of inter
tors: Categoris
National Indust
eference Poin
E certificate (c
aration of Past
ficate of Indep
orisation Decla
able, may inva
t of products o
conditional wri
Manufacturing
cial Requireme
O or proof of ow
pany cedings,
y of Licence to
y of Licence to
MRC of the bi
uirements an
y of the requi
stock availabi
BBEE, License
n bid;
of Bidder;
A certified cop
rest;
sation by race
trial Participati
nts Claimed (B
certified copy)
t SCM Practice
pendent Bid De
aration Note:
alidate the bid
offered sourced
itten undertaki
g Practice (GM
ents and Cond
wnership/share
, mergers and
o manufacture
o manufacture
dder (applican
nd Conditions
irements may
ility of any item
e to Manufactu
py of latest and
, gender and d
on Programm
-BBEE);
or Sworn Affid
es;
etermination;
Non-complian
;
d from third pa
ing from the th
MP). Declarati
itions of Conta
eholding. Cert
name change
e or import (in t
e medicines, in
nt);
s of Contract
y be deemed
m offered, non
ure, Certificate
d complete rep
disability;
e;
davit to claim p
ce to submiss
arty;
hird party;
on of complian
act. Declaratio
tified copies of
es;
the name of th
ncluding all an
: HP06-2021
to be non-re
-compliance;
es etc. Bid Sign
port. Note: CS
preference poi
sion of a valid
nce;
on of complian
f registration c
he bidder), inc
nnexures for lo
SVP
Page 16 o
esponsive and
nature;
SD summary r
ints;
d authorisation
ce;
certificates;
luding all anne
ocal manufactu
of 38
d will not be
report will not
n declaration,
exures;
uring sites as
9. CO
Bidd
mus
and
bid
info
Set
Bidd
field
copy
Bidd
Fina
S
Certified cop
(Annexure). N
filed in nume
Original Pac
Control Coun
product offe
filed/submitte
order;
Proof of sam
Bidder`s item
Signed Excel
Bid response
evaluation
MPLETION O
ders are requir
st be submitted
submitted in a
number and th
rmation reque
1: Hard copy
ders must com
d is provided b
y of the bid do
ders must sub
ancial Officer,
Special Requ
ies of Medicin
Note: All MRC
rical order;
kage Insert (P
ncil (MCC) or
red. Note: Al
ed in numerica
ple submissio
m list (List of pr
l Bid Respons
e Pricing Sch
OF DOCUME
red to submit t
d not later tha
a sealed pack
he closing date
ested is not rel
y legally bind
mplete all SBD
bidders must c
ocument will se
mit their comp
or authorised
uirements an
e Registration
C's must be ma
PI) or docum
r the South A
ll PI`s must
al
n;
roducts offered
se Pricing Sche
hedule is not
ENTS AND B
three sets of b
n the closing d
kage. The full n
e must be clea
evant this sho
ing bid docum
, PBD and Bid
omplete the fo
erve as the leg
plete bid in har
designee of th
nd Conditions
n Certificates (
arked by the b
ent detailing
African Health
be marked w
d); and
edule (All price
signed in the
BID SUBMIS
bid documents
date and time.
name and add
arly indicated o
ould be indicate
ments
d Response fo
orms in black i
gal bid docum
rd copy format
he entity subm
s of Contract
(MRC) with all
idder with the
professional i
h Products Re
with the relev
es must be su
e space provid
SION
s according to
. Set 2 and Se
dress of the bid
on the packag
ed with N/A.
orms in black in
nk, handwritte
ent.
t (paper docum
mitting the bid m
: HP06-2021
the associate
relevant item
information ap
egulatory Auth
vant item num
ubmitted in 2 (t
ded, the bid w
the instruction
et 3 must be in
dder, including
ge. All fields m
nk, typed. Whe
en in capital le
ment). The Ch
must sign the
SVP
Page 17 o
ed conditions o
number and b
pproved by th
hority (SAHPR
mber and be
two) decimals
will not be co
ns below. All th
ncluded on a C
g the return ad
must be comple
ere no electro
tters. The sign
hief Executive
official signatu
of 38
of registration
be sorted and
he Medicines
RA) for each
e sorted and
). If the Excel
onsidered for
hree sets
CD with Set 1
ddress, the
eted. Where
nic entry
ned hard
Officer, Chief
ure pages.
All p
not
As t
200
Bidd
Late
Bid
requ
two
unti
Set
Bidd
requ
Set
Bidd
Doc
All t
Bidd
unit
.
10. LAT
Bids
for c
S
pages in the co
acceptable. A
the National D
2, published in
ders must still
e bids will not
ders must ref
uested that b
o hole lever ar
ied for filing p
2: PDF of Ha
ders must sub
uested.
3: Electronic
ders must sub
cument and oth
three sets of in
ders must ens
pack as spec
TE BIDS
s received afte
consideration
Special Requ
omplete bid do
Any change/s m
Department of
n the Gazette
ensure that bi
be accepted fo
frain from us
bidders pre-pu
rch file. Bid d
purposes.
ard Copy, sign
mit a PDF ver
c version of b
mit the electro
her relevant s
nformation mu
sure that the p
cified. No conv
er the closing d
and, where pr
uirements an
ocument must
must be clearly
Health complie
18 March 202
ids are deliver
or consideratio
ing binding m
unch two hole
documents sh
ned legal doc
rsion of the en
bid documents
onic versions (
preadsheets in
st be submitte
rice quoted fo
version factors
date and time,
ractical, be ret
nd Conditions
t be initialed by
y indicated and
es with the reg
20 no briefing s
red on time to
on
methods like c
es on the left
hould be tied
cuments. (i.e.
tire signed ha
s
(editable pdf) o
n Excel (not pd
ed in order for
or a product (l
s will be applie
, at the addres
urned unopen
s of Contract
y same with b
d initialed.
gulations mad
session or pub
the correct ad
coil, comb, w
t hand side of
in parcels us
pdf of Set 1)
rdcopy bid, inc
of all SBD and
df).
the bid to be e
ine item) on th
ed.
ss indicated in
ed to the bidd
: HP06-2021
lack ink. The u
e under the D
blic bid openin
ddress and dep
wire velobind,
f bid docume
sing string or
cluding all cert
d PBD docume
evaluated.
he Bid Respon
the bid docum
er.
SVP
Page 18 o
use of correcti
isaster Manag
ng will be held.
posited in the
screw bindin
nts suitable f
rope that can
tificates and d
ents, Bid Resp
nse Document
ments, will not
of 38
ion fluid is
gement Act,
. However,
Tender Box.
ng etc. It is
for filing in a
n be easily
ocuments
ponse
t is for the
be accepted
11. CO
Bidd
con
12. FRO The
reco
them
com
The
part
accu
Guid
Indu
fron
bid/
sect
aga
13. SUP
The
any
the
14. CO
The
and
S
UNTER CON
ders’ attention
ditions by bidd
ONTING
e National Dep
ognises that re
mselves in acc
mpliant manner
e National Dep
t of the bid eva
uracy of the re
delines on Co
ustry, be estab
nting does not
contract and
tor for a period
inst the bidder
PPLIER DUE
e National Dep
time during th
site specified
MMUNICATI
e National Dep
time of the bi
Special Requ
NDITIONS
is drawn to th
ders may resu
partment of He
eal empowerm
cordance with
r. Against this
partment of He
aluation proce
epresentation
mplex Structu
blished during
exist. Failure t
may also resu
d not exceedin
r/contractor co
E DILIGENCE
partment of He
he contract pe
in the bid and
ION
partment of He
d and prior to
uirements an
he fact that am
lt in the invalid
ealth supports
ment can only b
the Constitutio
background, t
ealth, in ensuri
sses, conduct
made in bid do
res and Trans
such enquiry/
to do so within
ult in the restric
ng 10 years, in
oncerned.
E
ealth reserves
riod. This ma
the site comp
ealth, may com
the award of t
nd Conditions
mendments to a
dation of such
s the spirit of b
be achieved th
on and in an h
the National D
ng that bidder
t or initiate the
ocuments. Sh
sactions and F
/investigation,
n a period of 1
ction of the bid
n addition to an
the right to co
y include site
plies with quali
mmunicate with
the contract, o
s of Contract
any of the bid
bids.
road based bl
hrough individu
honest, fair, eq
Department of
rs conduct the
necessary en
ould any of the
Fronting, issue
the onus will b
4 days from d
dder/contracto
ny other reme
onduct supplier
visits to asses
ity criteria.
h bidders whe
or to extend the
: HP06-2021
conditions or
ack economic
uals and busin
quitable, transp
Health condem
mselves in an
nquiries/invest
e fronting indic
d by the Depa
be on the bidd
ate of notificat
or to conduct b
dies the Natio
r due diligence
ss whether an
re clarity is so
e validity perio
SVP
Page 19 o
setting of cou
c empowermen
nesses conduc
parent and leg
mns any form
honest mann
igations to det
cators as cont
artment of Trad
der/contractor t
tion, may inva
business with t
onal Treasury m
e prior to final
item is manuf
ught after the
od of the bid, if
of 38
nter
nt and
cting
gally
of fronting.
er will, as
termine the
tained in the
de and
to prove that
alidate the
the public
may have
award or at
factured at
closing date
f necessary.
Any
Dep
disc
All c
15. CO
Po
D
Pr
PR
00
Ple
S
y communicatio
partment of He
couraged.
communication
NTACT DET
ostal address
irectorate: Affo
rivate Bag X82
RETORIA
001
ease use the f
tenders@he
Special Requ
on to any gove
ealth in respec
n between the
TAILS
s
ordable Medic
28
following e-ma
ealth.gov.za
uirements an
ernment officia
ct of this bid be
e bidder and th
cines
ail address for
nd Conditions
al or a person
etween the clo
he National De
any queries re
s of Contract
acting in an a
osing date and
epartment of H
Physical ad
Directorate:
Civitas Build
242 Struben
Cnr Thabo S
Pretoria
0002
elating to bidd
: HP06-2021
advisory capac
the award of
Health, must be
ddress
Affordable Me
ding
Street
Sehume Street
ing process:
SVP
Page 20 o
city for the Nat
the bid by the
e done in writi
edicines
t
of 38
tional
bidder is
ng.
SECTI 16. C
T
17. P
P
N
P
O
18. R
A
af
F
S
ION B
CONTRACT P
he contract sh
PARTICIPATI
articipating Au
National Depar
rovincial Depa
Eastern Ca
Free State
Gauteng;
KwaZulu-N
Limpopo.
Other Institution
Nelson Ma
REGISTRATIO
All contracted s
fter award of c
ailure to meet
Special Requ
PERIOD
hall be for the
ING AUTHO
uthorities and
tments, Provin
artments:
ape;
;
Natal;
ns:
andela Children
ON ON DATA
suppliers must
contract.
this requirem
uirements an
period from 01
RITES AND
Health Establi
ncial Departme
ns' Hospital
ABASES OF
t register on th
ent will result
nd Conditions
1 May 2021 to
OTHER HEA
ishments whic
ents and orthe
F PARTICIPA
he supplier da
in the inability
s of Contract
o 30 April 2024
ALTH ESTAB
ch will be partic
er institutions a
Mp
No
No
W
ATING AUTH
atabases of Pa
to process pa
: HP06-2021
4.
BLISHMENT
cipating autho
as approved b
pumalanga;
orthern Cape;
orth West;
estern Cape; a
HORITIES
articipating Aut
ayment for goo
SVP
Page 21 o
S
orities in this co
by the account
and
thorities within
ods.
of 38
ontract are
ing officer.
n 30 days
Page 22 o
19. P
R
P
A
en
of
20. A
T
sa
T
T
co
T
aw
In
D
pa
no
si
th
of 38
POST AWAR
Regulation 16A
ublic Entities,
Accounting Offi
ntity, request t
f state, subjec
AWARD CON
he National D
ame item.
he National D
he National D
ontractors (two
he following a
ward:
Source o
Capacity
Estimate
Risk to p
Past com
n cases where
Department of
ack sizes suita
o conversion f
izes during ev
hat specified is
Spe
D PARTICIP
A6.6 of the Tre
issued in term
icer/Accountin
to participate i
ct to the written
NDITIONS
epartment of H
epartment of H
epartment of H
o or more) to a
re examples o
of Active Pharm
y to meet expe
ed volume to b
public health if
mpliance of the
the tender do
Health reserve
able for a 28-d
factor will be a
aluation. Simil
s offered.
ecial Conditio
PATION
easury Regulat
ms of the Publ
ng Authority ma
n any contrac
n approval of s
Health reserve
Health reserve
Health reserve
address high v
of consideratio
maceuticaI Ing
ected demand
be supplied;
f the item is no
e bidder with c
oes not achiev
es the right no
day treatment
applied. Direct
larly, no conve
ons of Contra
tions for Depa
lic Finance Ma
ay, on behalf o
t arranged by
such organ of
es the right to
es the right to
es the right to
volume require
ons which may
gredient (API)
as per publish
ot available;
contractual obl
e the most eco
ot to award tha
cycle are requ
comparisons
ersion factors w
act: HP06-20
artments, Trad
anagement Ac
of a departme
means of a co
state and the
award contrac
negotiate price
award the sam
ements, secur
y be taken into
and actual ma
hed estimates
ligations.
onomically ad
at item. In the c
uired. Should a
will be made b
will be applied
021SVP
ing Entities, C
ct, 1999, (Act 1
nt, constitution
ompetitive bidd
relevant contr
cts to more tha
es.
me item as a m
rity of supply a
o account whe
anufacturing s
in the Excel B
vantageous p
case of medic
a 30-day or oth
between the 2
d in cases whe
Constitutional E
1 of 1999), sta
nal institution o
ding process b
ractors.
an one contrac
multiple award
and product av
n contemplatin
site;
Bid Response
rice, the Natio
ines for chron
her pack size
28-day and oth
ere a pack size
Entities and
ates that the
or public
by any organ
ctor for the
to various
vailability.
ng a multiple
Document;
onal
ic conditions,
be offered,
her pack
e other than
Page 23 o
T
re
ite
an
th
T
H
ef
20.1 S
T
en
T
Tw
Categor
of 38
he National D
equired, due to
ems registered
nd time of bid
he contract for
he Departmen
However, in cas
ffect.
SPLIT AND M
he National D
nsure security
he following w
Source o
Capacity
Estimate
Risk to p
Past com
wo-way split a
ry
A
B
C
D
E
Spe
epartment of H
o emerging clin
d in terms of th
closure. In the
an item, or ad
nt of Health wi
ses where pat
MULTIPLE AW
epartment of H
y of supply.
will be taken in
of API and ma
y to meet expe
ed volume to b
public health if
mpliance of the
awards will be
ecial Conditio
Health may ch
nical evidence
he Medicines
ese circumstan
djust the quan
ll notify the co
tient safety is a
WARDS
Health reserve
to consideratio
nufacturing sit
ected demand
be supplied.
f the item is no
e bidder with c
made in acco
Differe
ons of Contra
hange treatme
e, disease prof
and Related S
nces, the Nati
tity awarded b
ontracted supp
a concern, the
es the right to
on when conte
te.
as per publish
ot available.
contractual obl
ordance with th
ence betweenscored
Equal points
< 5 points
>5-10 points
>10-20 points
>20 points
act: HP06-20
nt protocols a
files, safety or
Substances Ac
onal Departme
based on expe
plier within a re
ese changes m
issue split or m
emplating a sp
hed estimates
ligations.
he following sc
n points
s
021SVP
nd/or product
r resistance pa
ct, 1965, (Act 1
ent of Health r
ected changes
easonable time
may be implem
multiple award
plit award:
in the Bid Res
chedule based
Recommend
formulations w
atterns and ava
101 of 1965) a
reserves the ri
in projected d
e of the expec
mented with im
ds, where nece
sponse Docum
d on the points
ded percenta
50/50
60/40
70/30
80/20
90/10
where
ailability of
at the date
ight to cancel
demand.
ted change.
mediate
essary, to
ment.
s scored:
age split
Page 24 o
20.2 T
T
d
t
c
a
t
f
T
S
m
f
c
m
w
S
a
o
of 38
Where a split
volumes for a
For a thr
For a fou
THERAPEUT
The Policy for
defines a thera
therapeutic eff
class, may diff
action, result i
these medicin
for a specific in
The ministeria
Standard Trea
mentioned in t
followed by an
classes have b
member of the
where appropr
Such therapeu
advantageous
offering the op
A single mem
Spe
t for more than
award:
ree way split: S
ur way split: Su
TIC CLASS A
Classifying M
apeutic class a
fects. Medicine
fer in chemistr
n different adv
es have close
ndication.
ally appointed
atment Guideli
the “Medicine
n example suc
been designat
e class for a sp
riate.
utic classes m
s contract, offe
pportunity for c
mber of the cl
ecial Conditio
n 2 suppliers is
Supplier share
upplier share =
AWARDS
Medicines into T
as a group of
es in a therape
ry or pharmaco
verse reaction
e similarity in e
National Esse
nes (STGs) an
treatment” sec
ch as, HMGCo
ted where non
pecific indicati
ay be used du
er the market t
cost efficiencie
lass may be a
ons of Contra
s contemplate
e = 33.3% + (s
= 25% + (supp
Therapetic Cla
medicines wh
eutic class ma
okinetic prope
s, have differe
efficacy and sa
ential Medicine
nd Essential M
ction of the na
oA reductase ih
ne of the memb
on. The NEML
uring the contr
he largest volu
es by stimulati
awarded.
act: HP06-20
ed, the followin
supplier score
plier score - m
asses for Purp
ich have active
ay or may not
erties, and may
ent toxicity and
afety profiles, w
es List Commit
Medicines List
ational STGs w
hibitors (Statin
bers of the cla
LC will designa
racting process
ume and incre
ng robust com
021SVP
ng formula may
- mean score)
mean score) x 2
poses of Thera
e ingredients w
belong to the s
y possess diffe
d drug interact
when administ
ttee (NEMLC)
(EML). Thera
which provides
ns) e.g. simava
ass offer any s
ate therapeuti
s to achieve th
ease the numb
mpetition.
y be used to a
) x 2.3%
2%
apeutic Interch
with comparab
same pharma
erent mechani
tion profiles. In
tered in equipo
formulates an
peutic classes
s a class of me
astatin. These
ignificant bene
c classes for a
he most econo
ber of competit
allocate
hange
ble
cological
isms of
n most cases,
otent doses
nd revises the
s are
edicines
therapeutic
efit over
a condition,
omically
tors, thereby
Page 25 o
21 N
T
su
22. N
T
T
pr
In
re
23. P
T
co
ThC
Seri
of 38
NEGOTIATIO
he National D
uccessful bidd
NON-COMMIT
he National D
he right is also
rior to closing
n the event tha
emedy the ma
PRICE REVIE
he National D
ontract:
A routine a
An excepti
herapeutic lass and es Number Class 1
Class 2
Spe
ONS
epartment of H
der(s) post awa
TMENT
epartment of H
o reserved to w
of the bid and
at an incorrect
tter in any ma
EW
epartment of H
adjustment to m
onal adjustme
Therapeuticdescription
Surfactant - g
Surfactant - g
ecial Conditio
Health reserve
ard.
Health reserve
withdraw or am
d post award
award has be
nner it may de
Health envisag
mitigate foreig
ent to mitigate
c class
M
group 1 P
V
N
1
group 2 P
V
N
2
ons of Contra
es the right to
es the right no
mend any of th
een made, the
eem fit.
ges three type
n exchange flu
significant sho
Members of th
Phospholipids,
Vs
Natural Phosph
20mg in 1.5m
Phospholipids,
Vs
Natural Phosph
240mg in 3ml,
act: HP06-20
negotiate with
t to award, to
he bid conditio
National Depa
es of price revi
uctuations;
ort-term foreig
he therapeutic
Total (Beracta
holipids (Porac
ml, 1.5ml
Total (Beracta
holipids (Porac
3ml
021SVP
h the bidders p
award in part,
ons, by notice,
artment of Hea
ew processes
n exchange fl
c class
ant), 100mg/4
ctant alpha), in
ant), 200mg/8
ctant alpha), in
prior to award a
or in full.
in writing to a
alth reserves t
s for the duratio
uctuations; an
4ml, 1 Vial
ntra-tracheal s
8ml, 1 Vial
ntra-tracheal s
and with the
all bidders
the right to
on of this
nd
solution,
solution,
Page 26 o
23.1 E
E
T
A
23.1.1 IN
23.2 P O
pr
A
of 38
A systemat
ELIGIBILITY R
ligibility for pri
he submission
Assessment of
NSTRUCTION
The price b
version. The
Active
Formu
Packa
Logist
Gross
The sum o
The local +
(e.g. Portio
component
VAT must
Labour mu
Breakdown
The Nation
component
RICE ADJUS
Only the portion
rice breakdow
Adjustments ar
Spe
tic review of p
RELATING T
ce adjustment
n of a complet
the rationality
NS FOR PRICE
reakdown mu
e delivered pri
Pharmaceutic
ulation;
aging;
ics (this includ
margin (rema
f these catego
+ imported por
on of API attr
t).
be apportione
ust be apportio
n must be in p
nal Departme
ts of the bid pr
TMENTS REL
n of the bid pri
wn on the signe
e always calcu
ecial Conditio
rices for comp
TO RATE OF
ts relating to fo
e price breakd
y of this price b
E BREAKDOW
st be complet
ce must be div
cal Ingredients
des transportat
aining portion).
ories must be e
rtions of the fi
ributable to loc
d equally acro
oned appropria
ercentage form
ent of Health
rice, which ma
LATING TO F
ice facing fore
ed bid submiss
ulated using th
ons of Contra
parable produc
F EXCHANG
oreign exchan
down per instru
breakdown by
WN
ted on the sig
vided across f
s (API);
tion, warehous
.
equal to 100%
rst three comp
cal + Portion
oss all compon
ately across th
mat to the clos
reserves the
ay include aud
OREIGN EXC
eign exchange
sion.
he original awa
act: HP06-20
cts available in
E ADJUSTM
nge risk depen
uctions below
the National D
ned bid respo
five componen
sing and distri
% of the deliver
ponents must
of API attribu
nents and not
e relevant com
sest whole per
e right to eng
dit of invoices a
CHANGE RISK
risk will be ad
arded contract
021SVP
n the internatio
MENTS
ds on:
for all relevan
Department of
onse documen
nts
bution);
red price for th
add up to 100
utable to impo
regarded as a
mponents.
rcentage (e.g.
gage with bid
and related do
K
djusted. This p
ted price as th
onal market pl
nt products; an
Health.
nt as well as t
he line item.
0% within eac
ort = 100% of
a separate com
20%).
dders to verify
ocumentation.
portion is deter
he base.
ace.
nd
the electronic
ch component
f specific API
mponent.
y any of the
rmined by the
Page 27 o
P
ba
R
E
co
B
S
su
R
23.3 A
S
H
W
ad
F
Lo
of 38
rice adjustmen
ase average r
Rates are sourc
ligibility for fav
ompliance with
Base average
R
R
R
hould the bidd
ubmit the calc
Reserve Bank p
APPLICATION
canned copies
Health prior to t
Where no appli
djustment wou
oreign exchan
ogistics.
Spe
nts relating to
ate of exchang
ced from the R
vourable Contr
h contractual o
RoE for this t
Curren
Rand per US
Rand per Br
Rand per
Rand per Yuan
Rand per India
Rand per Dan
der make use
ulated averag
published rate
N FOR CONTR
s of signed ap
the submission
cation for an a
uld be favoura
nge adjustmen
ecial Conditio
foreign excha
ge (RoE) and
Reserve Bank
ractual Price A
obligations.
tender will be
cy
S Dollar
r Pound
Euro
Renminbi
an Rupee
ish Krone
of any currenc
e RoE for the
es for the spec
RACTUAL PR
pplications for
n dates detaile
adjustment rel
able to the Dep
nts may never
ons of Contra
ange will be ba
an adjustmen
(www.resbank
Adjustments m
e as follows, p
cy not mention
period 1 Janu
cific currency.
ICE ADJUSTM
price adjustme
ed in the table
ating to foreig
partment, this w
result in a pric
act: HP06-20
ased on the pe
t average RoE
k.co.za).
may be withdra
per currency:
Base Averagthe period
ned above, the
uary 2020 to 30
MENTS
ents must be r
es below.
n exchange ha
will be implem
ce exceeding t
021SVP
ercentage chan
E.
awn in light of e
:
ge Rates of Ex1 January 20
16.61
20.90
18.30
2.34
0.22
2.43
e bidder must s
0 June 2020 u
received by the
as been receiv
mented automa
the current Sin
nge between t
evidence of po
xchange Aver20 to 30 June
0
0
stipulate this c
using the Sout
e National De
ved and such
atically.
ngle Exit Price
the relevant
oor
rage for e 2020
clearly and
h African
partment of
an
e, ex
Page 28 o
23.4 R
S
ta
Review
1
2
3
4
5
23.5 E
S
be
in
Review
0.1
1.1
2.1
3.1
4.1
5.1
of 38
ROUTINE PRIC
chedules for r
able below:
w Peadju
01 May
01 Nove
01 May
01 Nove
01 May
XCEPTIONAL
uppliers may r
e activated if t
ndicated in the
w Period
01
01 Nove
01
01 Nove
01
01 Nove
Spe
CE ADJUSTM
routine price re
eriod for calustment ave
y 2021 - 31 O
ember 2021 -
y 2022 - 31 O
ember 2022 -
y 2023 - 31 O
L PRICE ADJ
request excep
the absolute ch
table below fl
d for calculataverage
May 2021 -
ember 2021 -
May 2022 -
ember 2022 -
May 2023 -
ember 2023 -
ecial Conditio
MENTS
eviews, and pe
lculating erage RoE
October 2021
- 30 April 202
October 2022
- 30 April 202
October 2023
USTMENTS
ptional price ad
hange betwee
luctuates by m
ting adjustme RoE
31 July 2021
- 31 January
31 July 2022
- 31 January
31 July 2023
- 31 January
ons of Contra
eriods for calc
Subreque
reviewo
1 03 No
22 03
2 03 No
23 03
3 03 No
djustments acc
en the base Ro
more than 10%
ment Sre
rev
1 0
2022 03
2 0
2023 03
3 0
2024 03
act: HP06-20
ulating adjustm
bmission of est for procew to reach thoffice by
ovember 202
May 2022
ovember 202
May 2023
ovember 202
cording to the
oE and the thr
%.
Submission equest for prview to reach
office by
03 August 20
3 February 2
03 August 20
3 February 2
03 August 20
3 February 2
021SVP
ment average
e he
Daadjube
21 01
0
22 01
0
23 01
schedule in th
ree month retro
of roce h the
Dadb
021 01
2022
022 01
2023
023 01
2024
RoE are deta
ate from whiusted prices
ecome effect
December 2
01 June 2022
December 2
01 June 202
December 2
he table below
ospective ave
Date from wdjusted pricebecome effe
1 September
01 March 20
1 September
01 March 20
1 September
01 March 20
iled in the
ich s will tive
2021
2
2022
3
2023
w. These will
rage RoE
which es will ctive
r 2021
022
r 2022
023
r 2023
024
Page 29 o
S
m
ad
Review
1
2
3
4
5
23.6 PR
Th
com
Wh
wil
Wh
rig
24. QU
Pro
Su
of 38
uppliers who r
months, rather
djustment ave
w Peadju
01 Augu
01 Feb
01 Augu
01 Feb
01 Augu
RICE ADJUST
e National De
mparable glob
here this revie
l enter into pri
here the outco
ht to terminate
UALITY
oducts must c
ubstances Act,
Spe
received exce
than the usua
erage RoE in th
eriod for calustment ave
ust 2021 - 31
bruary 2022 -
ust 2022 - 31
bruary 2023 -
ust 2023 - 31
TMENTS BAS
epartment of H
bal prices.
ew identifies an
ce negotiation
ome of this neg
e the award fo
onform to the
1965 (Act 10
ecial Conditio
ptional adjustm
al six month his
hese instance
lculating erage RoE
October 202
30 April 202
October 202
30 April 202
October 202
ED ON A SYS
ealth reserves
ny prices that a
ns with the con
gotiation is dee
or the item in q
conditions of
1 of 1965) for
ons of Contra
ments will rece
storical averag
s are detailed
Submisfor prreach
21 03 N
22 03
22 03 N
23 03
23 03 N
STEMATIC RE
s the right to re
are lower than
ntracted suppl
emed unfavou
uestion.
registration of
the full duratio
act: HP06-20
eive routine ad
ge exchange r
in the table be
ssion of reqroce review h the office
ovember 202
3 May 2022
ovember 202
3 May 2023
ovember 202
EVIEW
eview internat
n contract price
ier.
urable, the Nat
the product in
on of this cont
021SVP
djustments bas
rate. The perio
elow:
uest to by
Daadjube
21 01
0
22 01
0
23 01
ional prices to
es the Nationa
tional Departm
n terms of the
ract.
sed on the pre
ods for calculat
ate from whiusted prices
ecome effect
December 2
01 June 2022
December 2
01 June 202
December 2
o identify lowes
al Department
ment of Health
Medicines and
eceding three
ting
ich s will tive
2021
2
2022
3
2023
st
of Health
reserves the
d Related
Page 30 o
25. DE 25.1 DE
Fir
Tra
Th
con
the
Le
by
cal
Fa
22
25.2 QU
Th
qu
Pro
Na
reg
Su
alig
of 38
ELIVERY AN
ELIVERY BA
rm lead times f
ansit and stora
e initial lead ti
ntract and NO
e date of awar
ad time within
the Departme
lendar days.
ilure to comply
of the Genera
UANTITIES
e quantities re
antity which w
oposed minim
ational Departm
garding MOQs
uppliers are req
gned with the
Spe
ND QUANTIT
ASIS
for delivery mu
age conditions
me as propos
OT the date of
rd.
the contract p
ent, as confirm
y with the con
al Conditions o
eflected in the
will be procured
um order quan
ment of Health
s cannot be re
quired to main
needs of Part
ecial Conditio
TIES
ust be quoted
s applicable to
sed in the bid r
placement of t
period is define
med by the Pro
tractual lead t
of Contract.
bid are estima
d during the co
ntities (MOQs
h reserves the
ached, the bid
ntain sufficient
icipating Autho
ons of Contra
for the duratio
the relevant p
response docu
the first order.
ed as the time
oof of Delivery
ime will result
ated quantities
ontract period.
) should facilit
right to negot
d may not be a
buffer stock to
orities.
act: HP06-20
on of the contr
products must
ument will be c
This period m
e from submiss
document. Th
in penalties b
s and no guara
. Fluctuations
tate delivery d
iate MOQs wh
awarded.
o meet at leas
021SVP
ract period.
be adhered to
calculated from
may not exceed
sion of order to
his lead time m
eing enforced
antee is given
in monthly de
irectly to healt
here necessar
st two-months
o.
m date of awar
d 75 calendar
o supplier to ti
may not exceed
as per paragr
or implied as
mand may occ
th establishme
ry. Where cons
demand for al
rd of the
days from
ime of receipt
d 14
raph 21 and
to the actual
cur.
ents. The
sensus
ll items,
Page 31 o
SECTI 26. SU 26.1 Su
the
con
Na
Th
pe
of 38
ION C
UPPLIER PE
upplier perfor
e National Dep
ntractor and th
ational Departm
e National De
rformance of c
Compliance
As a minimu
mechanism
All trans
A mont
Product
Numbe
Numbe
Numbe
Status o
Attendance
The Na
not be
Supplie
efficien
The Particip
22 of the Ge
Non-complia
participation
Spe
RFORMANC
rmance mana
partment of He
he Participatin
ment of Health
epartment of H
contracted sup
e with reporting
um, suppliers
defined by the
sactional data
hly age analys
tion pipeline d
r of units of th
r of units of th
r of units of th
of outstanding
of compulsor
ational Departm
limited to, a
ers may be
cies in the sup
pating Authorit
eneral Conditio
ance of contr
n in future cont
ecial Conditio
CE MANAGE
gement will b
ealth and, whe
g Authority, N
h must be infor
ealth, in collab
ppliers in term
g requirements
will be require
e National Dep
relating to ord
sis;
data and foreca
e item availab
e item in Qual
e item in the c
g orders.
ry quarterly m
ment of Healt
review of su
required to p
pply chain to b
ties shall impo
ons of Contrac
racted supplie
tracts.
ons of Contra
EMENT
e the respons
ere supplier pe
ational Treasu
rmed for corre
boration with t
s of this contra
s according to
ed to submit th
partment of He
ders;
ast including:
ble (stock on h
lity Assurance
current month’
meetings
h will hold qu
upplier perform
present conti
benefit both su
ose penalties,
ct.
ers to the te
act: HP06-20
ibility of Partic
erformance dis
ury: Transvers
ective action.
he Participatin
act, including
o reporting sch
he following in
ealth:
and);
e, awaiting rele
s production p
arterly meetin
mance and fo
nuous improv
uppliers and th
where deeme
erms and con
021SVP
cipating Autho
sputes cannot
sal Contracting
ng Authorities,
but not limited
edule and rep
formation in a
ease;
plan.
ngs with suppl
orecasted dem
vement initiat
e Department
ed necessary,
nditions of thi
orities with ove
be resolved b
g Chief Directo
will monitor th
d to the followin
porting mechan
a specified form
iers which wil
mand for the
tives aimed
t of Health.
, as per Parag
is contract m
ersight from
between the
orate and
he
ng:
nism.
mat and via a
l include, but
next quarter.
at improving
graph 21 and
may influence
Page 32 o
26.2 D
of 38
Contractors
order(s) as w
Contractors
and delivery
The instruct
invoices mu
orders issue
The Departm
quantity.
In order to f
orders for th
Only orders
Suppliers a
Authorities,
Changes to
The Particip
lead time sp
to the same
paragraph 2
In cases w
contracted s
DELIVERY AD
Products a
delivery ins
The inform
requiremen
Invoices m
particular m
Related Su
Spe
should note
well as for the
should note t
y points will be
tions appearin
ust be strictly
ed by the purc
ment of Health
facilitate efficie
he health estab
made using a
are required
in a manner s
any quantities
pating Authorit
pecified in the
e quantity in
21.6 of the Gen
here an orde
supplier must l
HERENCE
and related do
structions stipu
mation on invo
nts as defined
must reflect b
medicine, and
ubstances Act
ecial Conditio
that each in
payment(s) th
that the order
e specified by t
ng on the offi
adhered to an
hasing institut
h is under no
ent implement
blishment as p
an official, auth
to acknowled
stipulated by th
s ordered may
ties reserve th
contract and m
substitution o
neral Conditio
r is received
liaise with the
ocumentation
ulated on the p
oices and doc
by the Nation
oth the "prop
d which is the
t, 1965 (Act 1
ons of Contra
ndividual purc
hereof.
r(s) will be pla
the relevant p
icial order for
nd under no c
tions.
obligation to
tation of the d
per the purcha
horised purcha
dge receipt o
he relevant Pa
y only be made
he right to can
may, at their d
of the goods
ons of Contract
which appea
relevant Parti
must be deli
purchase orde
cuments relat
nal Departmen
prietary name
e name appro
01 of 1965), a
act: HP06-20
chasing institu
aced as and w
urchasing inst
m regarding t
circumstances
accept any qu
irect delivery s
ase order.
ase order form
of all purcha
articipating Aut
e upon receipt
ncel orders w
iscretion, purc
not supplied
t).
ars to be irrat
cipating Autho
ivered in acco
er.
ing to deliver
t of Health.
"(brand nam
oved in terms
and the item d
021SVP
ution is respo
when required
titution(s).
the supply, di
s should the c
uantity which i
strategy, contr
mat are valid.
se orders re
thority.
t of an amende
here the lead
chase supplies
in conformity
ional or misa
ority prior to pr
ordance with
ry must comp
me"/"trade nam
of section 15
description as
onsible for ge
during the co
ispatch and s
contractor dev
is in excess o
racted supplie
eceived from
ed purchase o
time exceeds
s of a similar q
with the con
aligned with e
rocessing the o
the terms, co
ply with the m
me") which is
5(4) of the M
s it appears in
enerating the
ontract period
submission of
viate from the
of the ordered
ers must pack
Participating
order.
s the delivery
quality and up
ntract (as per
stimates, the
order.
onditions and
minimum data
unique to a
Medicines and
n the contract
Page 33 o
26.3 C
of 38
circular an
replace the
Original in
delivery po
may not be
know wher
The suppli
storage, as
receipt by t
Discrepanc
supplier wi
for the qua
Contracted
condition a
may recou
CONTINUITY O
Contracted
Contractor
Contractor
result in int
regula
any an
indust
challen
any ot
Contractor
as well as
Contractor
as well as
Spe
nd Master Pro
e MPC.
voices and p
oint. These do
e the same as
re documents
ier must ensu
s per product
the delegated
cies between
ithin a reasona
antities receive
d suppliers wil
as formally arr
p any expense
OF SUPPLY
d suppliers mu
s must mainta
s must inform
terrupted supp
atory action wh
nticipated prob
rial action
nges with man
ther supply cha
s must direct o
Participating A
s must direct
Participating A
ecial Conditio
ocurement Ca
proof of delive
cuments must
s the delivery a
must be delive
ure that produ
t's conditions
official.
invoice and p
able time or a
ed to be check
l be responsib
ranged in cons
es associated
ust have at lea
ain sufficient bu
National Dep
ply, including b
hich may impa
blems associat
nufacturing pip
allenges.
official commu
Authorities.
official commu
Authorities.
ons of Contra
talogue (MPC
ery must be a
t be delivered
address stipul
ered.
cts are delive
of registration
hysical stock,
as arranged w
ked upon recei
ble for collecti
sultation with t
with failure to
st two months
uffer stock thro
partment of He
but not limited
ct on their GM
ted with the av
peline;
unication relati
unication relat
act: HP06-20
C), or Master
authorised by
to the author
lated on the p
ered in accord
n. Delivery is
or damaged
ith the supplie
pt of delivery.
on of goods d
the purchasin
o collect such g
s' supply of the
oughout the d
ealth at first kn
to:
MP status or th
vailability of ac
ing to continuit
ting to paymen
021SVP
Health Produ
a delegated
ity responsible
purchase order
dance with the
deemed to te
stock, will be
er. This time p
delivered erron
g authority. Th
goods in accor
e estimate at th
uration of the
nowledge of a
hat of entities o
ctive pharmac
ty of supply to
nt challenges
uct List (MHPL
official at the
e for payment
r. Suppliers ar
e appropriate
erminate upon
reported to th
period must ma
neously, or in
he Participatin
rdance with th
he start of the
contract.
ny circumstan
on which they
eutical ingredi
o stockalert@h
to medacc@h
L), which will
e designated
. This may or
re required to
conditions of
signature of
he contracted
ake provision
the incorrect
ng Authorities
he agreement
contract.
nces that may
are reliant;
ient (API);
health.gov.za,
health.gov.za,
Page 34 o
26.4 R
N
a
T
r
w
of 38
All official
ensure con
It is the res
items. In th
source alte
not more t
sourced fro
In the even
Health rese
duration of
Prior to th
submit the
4.The con
information
Name of th
The quanti
The period
The alterna
This provis
supply of th
Suppliers m
the Genera
In terms of
Participatin
urgently re
REPORTING
National Depa
assisted with c
The National
requirements.
writing by the
Spe
communicatio
ntinuity of supp
sponsibility of
he event that t
ernative produ
than three m
om another co
nt that a contr
erves the righ
f the contracte
he supply of a
e samples of t
ntracted suppl
n:
he product to b
ties to be supp
d for which the
ative product m
sion is only ap
he product.
may be require
al Conditions o
f the General C
ng Authorities
quired and is
artment of He
complying with
Department
Any changes
Directorate: A
ecial Conditio
on must includ
ply.
the contracted
the contracted
uct of accepta
onths. In the
ontracted supp
racted supplie
t to proportion
d supplier’s in
an alternative
the product to
lier is also re
be supplied;
plied;and
e product will b
must be suppl
pplicable for e
ed to pay pena
of Contract Pa
Conditions of
may purchase
not immediate
ealth will prov
h these require
of Health m
s to reporting
Affordable Med
ons of Contra
de detail of c
d supplier to e
d supplier is u
ble quality an
case of a m
plier for the sam
er is unable to
nally reallocate
nability to supp
product can b
o be supplied
equired to fu
be supplied.
ied at the curr
emergency su
alties for supp
aragraph 22.
Contract and
e outside the c
ely available.
vide the requir
ements.
ay, from time
requirements
dicines.
act: HP06-20
orrective actio
ensure continu
nable to supp
d up to the sa
multiple award
me product.
o supply in the
e volumes to a
ply.
be undertaken
to the two he
urnish the De
rent price of th
upply and can
ply exceeding
Special Requ
contract in ord
rements for re
e to time an
or the reporti
021SVP
ons taken by
uous availabilit
ply, the contrac
ame quantity
, the alternati
e short term, t
an alternative
n, the contrac
ealth establish
epartment of
e contracted it
nnot be used f
the contractua
irements and
der to meet its
eporting and
d within reas
ng mechanism
the contracte
ty and supply
cted supplier i
as required fo
ive product sh
he National D
contracted su
cted supplier i
hments as list
Health with t
tem.
for routine an
al lead time as
Conditions of
s requirements
successful bid
son, add to t
m will be com
ed supplier to
of contracted
id required to
or a period of
hould not be
Department of
upplier for the
s required to
ed in section
the following
d continuous
s stipulated in
Contract, the
s if the item is
dders will be
the reporting
mmunicated in
Page 35 o
27. P
27.1 P
of 38
PACKAGING
PACKAGING
Suppliers
Packaging
Practice a
Packaging
adversely
The packa
acceptabl
The num
Documen
Where a
clearly illu
Where th
must be a
Oute
tamp
The c
when
Wher
be ad
Oute
tamp
The s
not a
The o
Spe
G, LABELLIN
must ensure
g must be su
and Good Dist
g must be su
y affect the sta
aging must be
le containers,
ber of units
nt.
particular stac
ustrated on the
e contents of
adhered to:
r packaging f
ering;.
contents must
n opened.
re the content
dhered to:
r packaging f
ering;.
shipper pack
llowed;.
outer packagin
ecial Conditio
NG AND BAR
e that product
itable for furth
tribution Practi
uitable for tran
bility and integ
e uniform for th
specifically de
per shipper p
cking and stor
e outer packag
the shipper p
flanges must
t be packed in
ts of a shipper
flanges must
must contain
ng must be cle
ons of Contra
RCODES
ts delivered a
her dispatch, s
ice.
nsportation an
grity of the pro
he duration of
eveloped for th
pack or origin
rage configura
ging.
pack represen
be sealed wi
n neat, uniform
r pack represe
be sealed wi
only one prod
early marked a
act: HP06-20
are received
storage and s
nd should pre
oduct.
the contract p
he product.
nal carton mu
ation is recom
t a standard s
th suitable ta
m rows and c
ent a non-stan
th suitable ta
duct, mixing of
as a "Part Box"
021SVP
in good orde
stacking accor
event exposur
period. All prod
ust be comple
mmended by th
supply quantit
ape that will c
columns that w
ndard supply q
ape that will c
f multiple prod
".
r at the point
rding to Good
re to condition
ducts must be
eted in the B
he supplier, th
ty of an item,
clearly display
will facilitate e
quantity, the fo
clearly display
ducts in a sing
t of delivery.
Wholesaling
ns that could
e packaged in
Bid Response
his should be
the following
y evidence of
easy counting
ollowing must
y evidence of
gle shipper is
Page 36 o
27.2
27
of 38
2 LABELLI
All co
not le
The f
part b
I
o
R
N
B
E
S
B
Wher
e.g. t
indica
Unit p
in ter
includ
.3 BARC
All
Th
Su
the
Spe
NG
ontainers, pack
ess than font s
following infor
boxes:
tem name as
or Master Hea
Registered pro
Number of uni
Batch number
Expiry date;
Storage condit
Barcode.
re the contents
thermolabile, h
ated on the ou
packs must be
rms of the Me
de a barcode s
CODES
unit and shipp
e European A
ppliers are en
e following info
Item name
(MPC), or M
The "proprie
approved by
Dosage
Pack siz
ecial Conditio
kaging and ca
size 48.
rmation must
contained in t
alth Products L
oduct name (if
ts in pack
;
tions;
s of the shippe
high-scheduled
uter packaging
e labelled in a
edicines and
suitable for the
per packs mus
Article Numberi
ncouraged to i
ormation:
as contained
Master Health P
etary name (
y MCC or SAH
e form and stre
ze;
ons of Contra
artons must be
be clearly and
the contract ci
List (MHPL), w
f applicable);
er pack require
d or cytotoxic
g on a brightly
ccordance wit
Related Subs
e identification
st be marked w
ing Code 13 (E
include a 2D b
d in the contr
Products List (
(brand name"
HPRA;
ength;
act: HP06-20
e clearly labelle
d indelibly prin
ircular and the
which will repla
e special atten
products, suc
coloured back
th Regulation
stances Act, 1
n and tracking
with the appro
EAN 13) has b
barcode or sim
act circular a
(MHPL) which
"/"trade name
021SVP
ed. Bulk packs
nted on all sh
e Master Procu
ce the MPC.
ntion in terms
ch instructions
kground.
10 of the Gen
965 (Act 101
of medication
priate barcode
been accepted
milar on their
and the Maste
will replace th
”) unique to
s must be labe
hipper packs, i
urement Cata
of storage and
must be clear
neral Regulatio
of 1965). Th
.
e number and
d as standard.
packaging tha
er Procureme
he MPC.
a particular
elled in letters
including any
logue (MPC),
d/or handling,
rly and visibly
ons published
he label must
symbology.
at will include
nt Catalogue
medicine, as
Page 37 o
28
29. CE Wh
a c
suc
Wh
sub
of 38
SHELF LIFE
Unless MCC
months upon
Contracted s
life provided t
Applicati
replaced
Applicati
Upon no
cost; and
Failure t
disposal
If short-date
will be appli
o A =
amo
disc
Unless othe
with a shelf-
EDING, MER
here a contrac
contract the co
ch an event.
here a contrac
bmit an officia
Spe
Batch n
Expiry d
E
or SAHPRA,
n delivery.
uppliers may a
that:
ions are accom
d or credited be
ions are appro
otification of re
d
to collect the
of the produc
ed products are
ed for invoicin
(12 – month
ount to be invo
count formula.
erwise agreed
-life of less tha
RGERS, TAK
cted supplier p
ontracted supp
cted supplier p
al request in wr
ecial Conditio
number;
date.
has approved
apply in writin
mpanied by an
efore or after e
oved by the Pa
emaining expir
products withi
ct by the Partic
e delivered wi
ng of short-date
s to date of e
oiced is: Cons
to, any Partic
an 12 months.
E OVERS AN
plans to merge
plier must infor
plans to cede a
riting to the ND
ons of Contra
d a shorter sh
g to Participat
n undertaking
expiry; and
articipating Au
red stock such
in 30 days aft
cipating Author
thout the afore
ed products:
expiry) x 2% x
signment value
cipating Autho
ND CHANGE
e with, or is go
rm the Nationa
a contrated ite
DOH, three mo
act: HP06-20
helf life, produ
ting Authorities
that such sho
thorities befor
h products will
ter written not
rity for the acc
ementioned un
x consignmen
e minus A, wh
ority may, with
ES IN SUPPL
ing to be acqu
al Department
m to another s
onths prior to t
021SVP
ucts must have
s to supply a p
ort-dated prod
re execution of
be collected b
tification to the
count of the su
ndertaking the
nt value short
here A is the v
hout prejudice,
LIER DETAIL
uired by, anoth
of Health in w
supplier, the c
the proposed
e a shelf-life o
product with a
ucts will be un
f orders; and
by the supplie
e supplier will
upplier.
e following disc
dated produc
value of the ou
, decline to ac
LS
her entity or pla
writing at first k
contracted sup
effective date.
of at least 12
a shorter shelf
nconditionally
r at their own
l result in the
count formula
ct. Therefore,
utcome of the
ccept product
ans to cede
knowledge of
plier must
.
Page 38 o
Th
su
Th
unt
Th
ad
30. CAN Ca
sub
Th
unt
31. THIR
P
N
of 38
he NDOH rese
upplier under t
e contracted s
til such time th
e contracted s
dress, name,
NCELLATION
ancellation of
bmitted to the
e contracted s
til such time th
RD PARTIES
articipating Au
No third party is
Spe
erves the right
he prevailing c
supplier is obli
hat the NDOH
supplier must i
or contact det
N OF THE CON
a contract will
satisfaction o
supplier is obli
hat the NDOH
uthorities will n
s entitled to pu
ecial Conditio
to accept or d
conditions of c
ged to supply
has approved
inform the Nat
ails and effect
NTRACT
only be consi
f the Departm
ged to supply
has approved
not make a pa
ut an account o
ons of Contra
decline the req
contract or to c
the contracted
d the request t
tional Departm
t these change
idered after co
ent of Health.
the contracted
d the request t
yment to or co
of a Participat
END
act: HP06-20
quest to cede t
cancel the con
d item under t
to cede the ite
ment of Health
es on the Cent
ompelling evide
d item under t
to cancel the it
onsult with a th
ing Authority o
021SVP
the contractua
ntract.
he prevailaing
m to another s
at first knowle
tral Supplier D
ence to suppo
he prevailaing
tem.
hird party.
on hold.
al obligations to
g conditions of
supplier.
edge of any ch
Database.
ort the request
g conditions of
o the new
f contract,
hanges to
t has been
f contract,
ITEM LIST HP06-2021SVP
Item No DescriptionTherapeutic Class
NumbersUnit Estimate
1 Acetylcysteine 200mg/ml, injection, 10ml Each 213,295
2 Adenosine 3mg/ml, injection, 2ml Each 74,740
3 Adrenaline (Epinephrine) 0.15mg/0.3ml, auto-injection, 0.3ml Each 5,570
4 Adrenaline (Epinephrine) 0.3mg/0.3ml, auto-injection, 0.3ml Each 2,336
5 Adrenaline (Epinephrine) 1mg/ml, injection, 1ml Each 7,520,710
6 Alfentanil 0.5mg/ml, injection, 2ml Each 119,310
7 Alprostadil 0.5mg/ml, injection, 1ml Each 6,250
8 Alteplase 50mg, 1 Vial Each 7,960
9 Aminophylline 25mg/ml, injection, 10ml Each 354,560
10 Amiodarone 50mg/ml, injection, 3ml Each 223,660
11 Atracurium 10mg/ml, injection, 2.5ml Each 81,270
12 Atracurium 10mg/ml, injection, 5ml Each 58,400
13 Atropine 0.5mg/ml, injection, 1ml Each 1,278,840
14 Atropine 1mg injection, 1ml Each 2,353,110
15 Betamethasone 4mg/ml, injection, 1ml Each 1,199,860
16 Biperiden 5mg, injection, 1ml Each 63,180
17 Bupivacaine 5mg, Adrenaline 5mcg/ml, injection, 20ml Each 292,780
18 Bupivacaine 5mg, Dextrose Anhydrous 72.7mg/ml, injection, 4ml Each 974,370
19 Bupivacaine 5mg/ml injection, spinal, 4ml Each 206,140
20 Bupivacaine 5mg/ml, injection, 10ml Each 971,660
21 Caffeine 20mg/ml, injection, 1ml Each 185,250
22 Calcium gluconate 10% m/v, injection, 10ml Each 754,340
23 Cisatracurium 2mg/ml, injection, 2.5 ml Each 266,650
24 Cisatracurium 2mg/ml, injection, 5ml Each 237,390
25 Clonazepam 1mg/ml, injection, 1ml Each 514,285
26 Clotiapine 10mg/ml, injection, 4ml Each 78,395
27 Dantrolene 20mg, injection, 70 ml Each 2,280
28 Desferrioxamine 500mg, injection Each 49,970
29 Desmopressin 4mcg, injection, 1ml Each 9,660
30 Dexamethasone 4mg, injection, 1ml Each 5,270,300
31 Dexmedetomidine, 100 mcg/ml, Injection for infusion, 2ml Each 58,320
32 Dextrose 50% m/v, injection, 20ml Each 1,293,980
33 Dextrose 50% m/v, injection, 50ml Each 1,140,740
34 Diazepam 5mg/ml, injection, 2ml Each 771,330
35 Diclofenac 25mg/ml, injection, 3ml Each 8,327,390
36 Digoxin 0,25mg/ml, injection, 2ml Each 39,280
37 Dinoprost 5mg, injection, 1ml Each 900
38 Dobutamine 12.5mg/ml, injection, 20ml Each 206,440
39 Dopamine 40mg/ml, injection, 5ml Each 106,755
40 Enoxaparin 40mg, injection, 0.4ml Each 8,663,680
41 Enoxaparin 60mg, injection, 0.6ml Each 901,800
42 Enoxaparin 80mg, injection, 0.8ml Each 2,019,230
43 Ephedrine 50mg, injection, 1ml Each 325,270
44 Ergometrine 0.5mg, injection, 1ml Each 24,700
45 Erythropoietin 10 000 iu, injection, 0.6ml Each 88,800
46 Erythropoietin 2 000 iu, injection, 0.3ml Each 320,510
47 Erythropoietin 30 000 iu, injection, 0.6ml Each 6,520
48 Erythropoietin 4 000 iu, injection, 0.3ml Each 683,630
Page 1 of 4
ITEM LIST HP06-2021SVP
Item No DescriptionTherapeutic Class
NumbersUnit Estimate
49 Erythropoietin 6 000 iu, injection, 0.3ml Each 13,624
50 Etomidate 2mg/ml, injection, 10ml Each 145,080
51 Fentanyl 0.05mg/ml, injection, 2ml Each 1,581,570
52 Fentanyl 0.05mg/ml, injection, 10ml Each 370,850
53 Fluorescein 100mg/ml, injection, 5ml Each 1,536
54 Flupenthixol decanoate 20mg/ml, injection, 1ml Each 1,507,530
55 Furosemide 10mg/ml, injection, 25ml Each 245,280
56 Furosemide 10mg/ml, injection, 2ml Each 7,085,900
57 Furosemide 10mg/ml, injection, 5ml Each 342,230
58 Glucagon 1mg, injection, 1ml Each 30,050
59 Glyceryl trinitrate 1mg/ml, injection, 10ml Each 146,900
60 Glycopyrronium bromide 0.2mg/ml, injection, 2ml Each 622,200
61 Haloperidol 10mg/ml, injection, 2ml Each 24,220
62 Haloperidol 5mg/ml, injection, 1ml Each 447,790
63 Heparin 1000 iu/ml, injection, 5ml Each 693,310
64 Heparin 5000 iu/ml, injection, 5ml Each 946,240
65 Hydrocortisone 100mg/2ml, injection, 2ml Each 4,166,740
66 Hyoscine Butylbromide 20mg, injection, 1ml Each 2,338,110
67 Insulin analogue, Human, Long-acting, 100 u/ml, disposable pen, 3ml Each 33,860
68 Insulin analogue, Human, Ultrafast-acting 100 u/ml, disposable pen, 3ml Each 229,559
69 Insulin analogue, Human, Ultrafast-acting 100 u/ml, vial, 10ml Each 1,540
70 Insulin, Biosynthetic, Human, Isophane, 100 u/ml, disposable pen, 3ml Each 2,832,200
71 Insulin, Biosynthetic, Human, Isophane, 100 u/ml, vial, 10ml Each 903,640
72 Insulin, Biosynthetic, Human, Biphasic, 100 u/ml, soluble 30% and Isophane 70%, disposable pen, 3ml Each 11,488,740
73 Insulin, Biosynthetic, Human, Biphasic, 100 u/ml, soluble 30% and Isophane 70%, penfilll cartridge for use in
pens, 3ml
(PENS TO BE PROVIDED FREE OF CHARGE TO PATIENTS)
Each 2,188,000
74 Insulin, Biosynthetic, Human, Biphasic, 100 u/ml, soluble 30% and Isophane 70%, vial, 10ml Each 4,520,360
75 Insulin, Biosynthetic, Human, Soluble, 100 u/ml, disposable pen, 3ml Each 1,886,440
76 Insulin, Biosynthetic, Human, Soluble, 100 u/ml, vial, 10ml Each 387,840
77 Iron dextran containing elemental iron 50mg/ml, injection, 10ml Each 16,500
78 Iron dextran containing elemental iron 50mg/ml, injection, 2ml Each 211,350
79 Iron sucrose containing elemental iron 20mg/ml, injection, 5ml Each 271,550
80 Isulin analogue, Human, Ultrafast-acting 100 u/ml, penfill cartridge for use in pens, 3ml
(PENS TO BE PROVIDED FREE OF CHARGE TO PATIENTS)
Each 7,725
81 Ketamine 10mg/ml, injection, 20ml Each 96,930
82 Ketamine 100mg/ml, injection, 10ml Each 61,060
83 Ketamine 50mg/ml, injection, 10ml Each 87,050
84 Labetalol 5mg/ml, injection, 20ml Each 193,390
85 Lidocaine 1% m/v, injection, not for iv use, 20ml Each 1,821,100
86 Lidocaine 10% m/v, iv injection, 5ml Each 39,220
87 Lidocaine 2% m/v injection, not for iv use, 20ml Each 1,191,930
88 Lidocaine 2% m/v, Adrenaline 12.5mcg (1:80 000), dental cartridge, 1.8ml Each 18,119,370
89 Lidocaine 2% m/v, dental cartridge, 1.8ml Each 2,814,860
90 Lidocaine 2% m/v, iv injection, 5ml Each 1,964,420
91 Lorazepam 4mg, injection, 1ml Each 977,050
92 Magnesium sulfate 50%, injection, 2ml Each 5,111,040
93 Mannitol 25% m/v, injection, 50ml Each 19,320
94 Methylprednisolone 125mg, (as sodium succinate) injection, 2ml Each 33,765
Page 2 of 4
ITEM LIST HP06-2021SVP
Item No DescriptionTherapeutic Class
NumbersUnit Estimate
95 Methylprednisolone 40mg, (as sodium succinate) injection, 1ml Each 5,160
96 Methylprednisolone 500mg, (as sodium succinate) injection, 8ml Each 100,830
97 Methylprednisolone acetate 40mg/ml, injection, 2ml Each 257,150
98 Methylprednisolone acetate 40mg/ml, injection, 5ml Each 18,412
99 Metoclopramide 5mg/ml, injection, 2ml Each 7,601,990
100 Midazolam 1mg/ml, injection, 5ml Each 595,200
101 Midazolam 5mg/ml, injection, 10ml Each 127,300
102 Midazolam 5mg/ml, injection, 3ml Each 948,930
103 Morphine 10mg/ml, injection, 1ml Each 3,307,110
104 Morphine 15mg/ml, injection, 1ml Each 1,772,750
105 Naloxone 0.02mg/ml, injection, 2ml Each 96,540
106 Naloxone 0.4mg/ml, injection, 1ml Each 504,980
107 Natural Phospholipids (Poractant alpha), intra-tracheal solution, 120mg in 1.5ml, 1.5ml Class 1 Each 35,215
108 Natural Phospholipids (Poractant alpha), intra-tracheal solution, 240mg in 3ml, 3ml Class 2 Each 17,274
109 Needle, Insulin, 31G x 5mm, sterile, suitable for use with all prefilled insulin injection devices, 100 Each 82,770
110 Needle, Insulin, 31G x 8mm, sterile, suitable for use with all prefilled insulin injection devices, 100 Each 377,460
111 Neostigmine 0.5mg, injection, 1ml Each 107,590
112 Neostigmine 2.5mg, injection, 1ml Each 481,450
113 Octreotide 0.05mg, injection, 1ml Each 14,020
114 Octreotide 0.1mg, injection, 1ml Each 119,395
115 Octreotide 0.2mg/ml, injection, 5ml Each 8,380
116 Oxytocin 10 iu, injection, 1ml Each 6,406,260
117 Oxytocin 5 iu, injection, 1ml Each 2,063,960
118 Oxytocin 5iu, Ergometrine 0.5mg, injection, 1ml Each 538,290
119 Pantoprazole 40mg, injection, 10ml Each 1,042,800
120 Paracetamol 10mg/ml, injection for IV infusion, 100ml Each 1,585,240
121 Paracetamol 10mg/ml, injection for IV infusion, 50ml Each 6,910
122 Pethidine 25mg/ml, injection, 1ml Each 354,260
123 Pethidine 50mg/ml, injection, 1ml Each 1,815,320
124 Pethidine 50mg/ml, injection, 2ml Each 2,769,710
125 Phenylephrine 10mg, injection, 1ml Each 637,460
126 Phenytoin 50mg/ml, injection, 5ml Each 1,278,200
127 Phospholipids, Total (Beractant), 100mg/4ml, 1 Vial Class 1 Each 35,215
128 Phospholipids, Total (Beractant), 200mg/8ml, 1 Vial Class 2 Each 17,274
129 Potassium Chloride 15%, m/v injection, 10ml Each 2,470,180
130 Potassium Phosphate Monobasic, Anhydrous, Potassium Phosphate Dibasic Anhydrous, 1.09g/1.05g,
injection, 10ml
Each 131,090
131 Promethazine 25mg/ml, injection, 1ml Each 691,430
132 Promethazine 25mg/ml, injection, 2ml Each 319,811
133 Propofol 10mg/ml, injection, 20ml Each 1,446,630
134 Propofol 10mg/ml, injection, 50ml Each 195,590
135 Protamine 10mg/ml, injection, 5ml Each 52,140
136 Quinine 300mg, injection, 1ml Each 46,610
137 Ranitidine 25mg/ml, injection, 2ml Each 822,410
138 Remifentanil 2mg, injection, 5ml Each 47,070
139 Rocuronium 50mg, injection, 5ml Each 777,100
140 Salbutamol 0.5mg, injection, 1ml Each 301,240
141 Sodium bicarbonate 4% m/v, injection, 50ml Each 109,550
Page 3 of 4
ITEM LIST HP06-2021SVP
Item No DescriptionTherapeutic Class
NumbersUnit Estimate
142 Sodium bicarbonate 8.5% m/v, injection, 50ml Each 578,010
143 Sodium chloride 0.9% m/v, injection, 10ml Each 12,400,540
144 Somatropin 15iu, powder for injection, cartridge + diluent Each 23,720
145 Somatropin 30iu, powder for injection, cartridge + diluent Each 24,895
146 Somatropin 36iu, powder for injection, cartridge + diluent Each 426
147 Streptokinase 1.5MU injection Each 10,155
148 Suxamethonium 50mg/ml, injection, 2ml Each 635,010
149 Testosterone 1g injection, 1 injection Each 16,415
150 Thiopentone 0.5g, injection, 20ml Each 23,540
151 Tramadol 50mg/ml, injection, 2ml Each 3,207,480
152 Tranexamic Acid 100mg/ml, injection, 5ml Each 1,734,980
153 Vecuronium 4mg, injection, 2ml Each 53,840
154 Verapamil HCl 2.5mg/ml, injection, 2ml Each 17,910
155 Vitamin B Complex, injection, 10ml Each 429,600
156 Vitamin B1 (Thiamine) 100mg/ml, injection, 10ml Each 412,200
157 Vitamin B12 (Cyanocobalamin) 1000mcg, injection, 1ml Each 487,350
158 Vitamin K1 (Phytomenadione) 10mg/1ml, injection Each 773,990
159 Vitamin K1 (Phytomenadione) 2mg/0.2ml, injection Each 3,500,390
160 Water for injection BP, injection, 10ml Each 37,241,680
161 Water for injection BP, injection, 20ml Each 4,112,500
162 Zuclopenthixol acetate 50mg, injection, 1ml Each 228,680
163 Zuclopenthixol decanoate 200mg/ml, injection, 1ml Each 2,142,750
Page 4 of 4